Biomarin Pharmaceutical Inc
Buy, Hold or Sell?

Let's analyse Biomarin together

Penke I guess you are interested in Biomarin Pharmaceutical Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biomarin Pharmaceutical Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Biomarin Pharmaceutical Inc

I send you an email if I find something interesting about Biomarin Pharmaceutical Inc.

Quick analysis of Biomarin (30 sec.)

What can you expect buying and holding a share of Biomarin? (30 sec.)

How much money do you get?

$0.37

When do you have the money?

1 year

How often do you get paid?

12.5%

What is your share worth?

Current worth

$25.81

Expected worth in 1 year

$27.23

How sure are you?

75.0%

+ What do you gain per year?

Total Gains per Share

$1.79

Return On Investment

2.0%

For what price can you sell your share?

Current Price per Share

$90.07

Expected price per share

$78.87 - $99.25

How sure are you?

50%

1. Valuation of Biomarin (5 min.)

Live pricePrice per Share (EOD)

$90.07

Book Value per Share

$25.81

Intrinsic Value Per Share

$-2.57 - $17.47

Total Value Per Share

$23.24 - $43.28

My calculation of the intrinsic value of Biomarin is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.16) 3Y: ($0.13) TTM: ($0.07)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.00) 3Y: ($0.02) TTM: ($0.03)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-0.59	$0.68	$-0.59 - $0.81
2	$-1.09	$1.64	$-0.52 - $1.13
3	$-1.50	$2.87	$-0.45 - $1.44
4	$-1.83	$4.33	$-0.38 - $1.75
5	$-2.09	$6.03	$-0.32 - $2.06
6	$-2.29	$7.94	$-0.25 - $2.37
7	$-2.43	$10.05	$-0.18 - $2.69
8	$-2.52	$12.35	$-0.11 - $3.00
9	$-2.57	$14.83	$-0.05 - $3.31
10	$-2.57	$17.47	$0.02 - $3.62

2. Growth of Biomarin (5 min.)

Is Biomarin growing?

	Current year	Previous year	Grow	Grow %
How rich?	$4.9b	$4.5b	$305.6m	6.3%

How much money is Biomarin making?

	Current year	Previous year	Grow	Grow %
Making money	$41.9m	$35.3m	$6.5m	15.6%
Net Profit Margin	7.0%	6.8%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Biomarin (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#14 / 1016

Most Revenue
#28 / 1016

Most Profit
#54 / 1016

Most Efficient
#130 / 1016

What can you expect buying and holding a share of Biomarin? (5 min.)

Welcome investor! Biomarin's management wants to use your money to grow the business. In return you get a share of Biomarin.

What can you expect buying and holding a share of Biomarin?

First you should know what it really means to hold a share of Biomarin. And how you can make/lose money.

Speculation

The Price per Share of Biomarin is $90.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Biomarin.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biomarin, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $25.81. Based on the TTM, the Book Value Change Per Share is $0.35 per quarter. Based on the YOY, the Book Value Change Per Share is $0.44 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.09 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Biomarin.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	0.11	0.1%	0.22	0.2%	0.18	0.2%	0.27	0.3%	-0.01	0.0%
Usd Book Value Change Per Share	0.20	0.2%	0.35	0.4%	0.44	0.5%	0.50	0.6%	0.47	0.5%
Usd Dividend Per Share	0.00	0.0%	0.09	0.1%	0.04	0.0%	0.03	0.0%	0.01	0.0%
Usd Total Gains Per Share	0.20	0.2%	0.45	0.5%	0.48	0.5%	0.53	0.6%	0.48	0.5%
Usd Price Per Share	96.42	-	92.21	-	87.06	-	86.98	-	88.95	-
Price to Earnings Ratio	226.96	-	125.00	-	-5,008.30	-	-950.66	-	-544.01	-
Price-to-Total Gains Ratio	491.71	-	26.34	-	-30.40	-	-81.32	-	37.70	-
Price to Book Ratio	3.74	-	3.70	-	3.66	-	4.21	-	5.83	-
Price-to-Total Gains Ratio	491.71	-	26.34	-	-30.40	-	-81.32	-	37.70	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	90.07
Number of shares	11

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.09	0.03
Usd Book Value Change Per Share	0.35	0.50
Usd Total Gains Per Share	0.45	0.53
Gains per Quarter (11 shares)	4.91	5.84
Gains per Year (11 shares)	19.65	23.35

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	4	16	10	1	22	13
2	8	31	30	2	44	36
3	12	47	50	4	67	59
4	16	62	70	5	89	82
5	20	78	90	6	111	105
6	25	93	110	7	133	128
7	29	109	130	8	155	151
8	33	124	150	9	177	174
9	37	140	170	11	200	197
10	41	156	190	12	222	220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	4.0	0.0	0.0	100.0%	8.0	4.0	0.0	66.7%	13.0	7.0	0.0	65.0%	15.0	25.0	0.0	37.5%	25.0	75.0	0.0	25.0%
Book Value Change Per Share	3.0	1.0	0.0	75.0%	10.0	2.0	0.0	83.3%	16.0	4.0	0.0	80.0%	30.0	10.0	0.0	75.0%	64.0	35.0	1.0	64.0%
Dividend per Share	3.0	0.0	1.0	75.0%	5.0	0.0	7.0	41.7%	5.0	0.0	15.0	25.0%	5.0	0.0	35.0	12.5%	5.0	0.0	95.0	5.0%
Total Gains per Share	3.0	1.0	0.0	75.0%	10.0	2.0	0.0	83.3%	16.0	4.0	0.0	80.0%	30.0	10.0	0.0	75.0%	64.0	35.0	1.0	64.0%

Fundamentals of Biomarin

About Biomarin Pharmaceutical Inc

https://www.biomarin.com
Biotechnology
3401
770 Lindaro Street, San Rafael, CA, United States, 94901
Google Maps Bing Maps

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Fundamental data was last updated by Penke on 2024-04-11 02:48:05.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Biomarin Pharmaceutical Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Biomarin earns for each $1 of revenue.

Above 10% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
A Net Profit Margin of 3.2% means that $0.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biomarin Pharmaceutical Inc:

The MRQ is 3.2%. The company is making a profit. +1
The TTM is 7.0%. The company is making a profit. +1

Trends

Current period		Compared to		+/-
MRQ	3.2%	TTM	7.0%	-3.9%
TTM	7.0%	YOY	6.8%	+0.2%
TTM	7.0%	5Y	10.5%	-3.5%
5Y	10.5%	10Y	-5.4%	+15.9%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.2%	-197.2%	+200.4%
TTM	7.0%	-210.4%	+217.4%
YOY	6.8%	-279.3%	+286.1%
5Y	10.5%	-436.8%	+447.3%
10Y	-5.4%	-599.3%	+593.9%

Measures how much net profit Biomarin earns for each $1 of revenue.

Revenue is the amount of profit Biomarin generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Biomarin earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Biomarin makes more profit. This shows the investor how efficiently Biomarin is operating in general and compared to other companies in the same industry. Biomarin operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Biomarin. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Biomarin is 0.03. This means that Biomarin earned $0.03 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -197.2%.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Biomarin with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Biomarin sells assets (profit will increase while costs remain the same).
It won’t show what part of Biomarin is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Biomarin

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Biomarin = 20,375
Total revenue MRQ Biomarin = 646,207
$20,375 / $646,207 = 0.03 or 3.2%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Biomarin is using its assets to generate profit.

Above 5% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
0.3% Return on Assets means that Biomarin generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biomarin Pharmaceutical Inc:

The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
The TTM is 0.6%. Using its assets, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	0.3%	TTM	0.6%	-0.3%
TTM	0.6%	YOY	0.6%	+0.1%
TTM	0.6%	5Y	0.9%	-0.2%
5Y	0.9%	10Y	-0.4%	+1.3%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.3%	-13.6%	+13.9%
TTM	0.6%	-12.9%	+13.5%
YOY	0.6%	-11.9%	+12.5%
5Y	0.9%	-14.2%	+15.1%
10Y	-0.4%	-16.2%	+15.8%

Shows how efficient Biomarin is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Biomarin is using its resources to generate profit. If the return on assets (0.3%) from Biomarin are higher than the Biotechnology mean (-13.6%) that means Biomarin is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Biomarin is 0.3%. This means the company generated $0.00 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.6%.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Biomarin

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Biomarin = 20,375
Total assets MRQ (balance sheet) from Biomarin = 6,841,603
20,375 / 6,841,603 = 0.00 or 0.3%

ROA is an important ratio as it will tell you how effectively Biomarin is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Biomarin is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
0.4% Return on Equity means Biomarin generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biomarin Pharmaceutical Inc:

The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
The TTM is 0.9%. Using its investors money, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	0.4%	TTM	0.9%	-0.5%
TTM	0.9%	YOY	0.8%	+0.1%
TTM	0.9%	5Y	1.3%	-0.4%
5Y	1.3%	10Y	-0.7%	+2.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.4%	-17.0%	+17.4%
TTM	0.9%	-16.1%	+17.0%
YOY	0.8%	-15.4%	+16.2%
5Y	1.3%	-20.0%	+21.3%
10Y	-0.7%	-21.1%	+20.4%

Shows how efficient Biomarin is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Biomarin is 0.4%. This means Biomarin generated $0.00 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -17.0%.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if Biomarin existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Biomarin

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Biomarin = 20,375
Shareholders equity (balance sheet) MRQ Biomarin = 4,951,549
20,375 / 4,951,549 = 0.00 or 0.4%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Biomarin Pharmaceutical Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Biomarin is operating .

Measures how much profit Biomarin makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
An Operating Margin of 2.2% means the company generated $0.02 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biomarin Pharmaceutical Inc:

The MRQ is 2.2%. The company is operating less efficient.
The TTM is 6.5%. The company is operating less efficient.

Trends

Current period		Compared to		+/-
MRQ	2.2%	TTM	6.5%	-4.3%
TTM	6.5%	YOY	2.8%	+3.7%
TTM	6.5%	5Y	-1.0%	+7.4%
5Y	-1.0%	10Y	-8.6%	+7.6%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.2%	-286.1%	+288.3%
TTM	6.5%	-224.4%	+230.9%
YOY	2.8%	-288.4%	+291.2%
5Y	-1.0%	-475.2%	+474.2%
10Y	-8.6%	-624.7%	+616.1%

Measures how efficient Biomarin is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Biomarin to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Biomarin is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Biomarin is 2.2%. This means that Biomarin earned $0.02 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -286.1%.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Biomarin

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Biomarin = 14,219
Total revenue MRQ Biomarin = 646,207
$14,219 / $646,207 = 0.02 or 2.2%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Biomarin is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.98 means that the operating costs are $0.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Biomarin Pharmaceutical Inc:

The MRQ is 0.978. The company is less efficient in keeping operating costs low.
The TTM is 0.935. The company is less efficient in keeping operating costs low.

Trends

Current period		Compared to		+/-
MRQ	0.978	TTM	0.935	+0.043
TTM	0.935	YOY	0.980	-0.045
TTM	0.935	5Y	1.020	-0.085
5Y	1.020	10Y	1.104	-0.085

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.978	2.997	-2.019
TTM	0.935	3.247	-2.312
YOY	0.980	3.766	-2.786
5Y	1.020	5.675	-4.655
10Y	1.104	7.857	-6.753

Measures how efficient Biomarin is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Biomarin to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Biomarin is 97.8%. This means that Biomarin earned $0.98 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.00.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Biomarin

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(135,478 +496,510) \ 646,207 = 0.98

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Biomarin Pharmaceutical Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Biomarin is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 25.11 means the company has $25.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Biomarin Pharmaceutical Inc:

The MRQ is 25.115. The company is very able to pay all its short-term debts. +2
The TTM is 9.337. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	25.115	TTM	9.337	+15.778
TTM	9.337	YOY	5.030	+4.306
TTM	9.337	5Y	5.220	+4.117
5Y	5.220	10Y	4.654	+0.566

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	25.115	3.930	+21.185
TTM	9.337	4.251	+5.086
YOY	5.030	5.436	-0.406
5Y	5.220	6.045	-0.825
10Y	4.654	6.363	-1.709

Measures if Biomarin is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Biomarin if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Biomarin is 25.11. This means Biomarin has $25.11 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.93.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Biomarin

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
2,956,088 \ 117,702) = 25.11

The current ratio measures if Biomarin is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Biomarin is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Biomarin does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Biomarin is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Biomarin is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Biomarin to the Biotechnology industry mean.
A Quick Ratio of 17.21 means the company can pay off $17.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biomarin Pharmaceutical Inc:

The MRQ is 17.215. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 6.657. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	17.215	TTM	6.657	+10.557
TTM	6.657	YOY	4.142	+2.515
TTM	6.657	5Y	4.121	+2.536
5Y	4.121	10Y	4.025	+0.096

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	17.215	3.629	+13.586
TTM	6.657	4.065	+2.592
YOY	4.142	5.397	-1.255
5Y	4.121	5.993	-1.872
10Y	4.025	6.277	-2.252

1.4. Solvency of Biomarin Pharmaceutical Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Biomarin assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Biomarin to Biotechnology industry mean.
A Debt to Asset Ratio of 0.28 means that Biomarin assets are financed with 27.6% credit (debt) and the remaining percentage (100% - 27.6%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Biomarin Pharmaceutical Inc:

The MRQ is 0.276. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.275. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.276	TTM	0.275	+0.002
TTM	0.275	YOY	0.273	+0.002
TTM	0.275	5Y	0.300	-0.025
5Y	0.300	10Y	0.329	-0.029

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.276	0.332	-0.056
TTM	0.275	0.334	-0.059
YOY	0.273	0.268	+0.005
5Y	0.300	0.366	-0.066
10Y	0.329	0.390	-0.061

Measures how much % of Biomarin assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Biomarin than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Biomarin to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Biomarin is 0.28. This means means that Biomarin is financed with 27.6% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 393.0%.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Biomarin has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Biomarin

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
1,890,054 \ 6,841,603 = 27.6% or 0.28.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Biomarin is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Biomarin to the Biotechnology industry mean.
A Debt to Equity ratio of 38.2% means that company has $0.38 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biomarin Pharmaceutical Inc:

The MRQ is 0.382. The company is very able to pay all its debts with equity. +2
The TTM is 0.379. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.382	TTM	0.379	+0.003
TTM	0.379	YOY	0.375	+0.003
TTM	0.379	5Y	0.431	-0.053
5Y	0.431	10Y	0.497	-0.065

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.382	0.381	+0.001
TTM	0.379	0.390	-0.011
YOY	0.375	0.334	+0.041
5Y	0.431	0.434	-0.003
10Y	0.497	0.466	+0.031

Measures if Biomarin is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Biomarin is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Biomarin is 0.38. This means that Biomarin can pay off $0.38 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.38.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Biomarin

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
1,890,054 \ 4,951,549 = 0.38 or 38.2%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Biomarin Pharmaceutical Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Biomarin generates.

Above 15 is considered overpriced but always compare Biomarin to the Biotechnology industry mean.
A PE ratio of 226.96 means the investor is paying $226.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biomarin Pharmaceutical Inc:

The EOD is 212.010. Based on the earnings, the company is expensive. -2
The MRQ is 226.957. Based on the earnings, the company is expensive. -2
The TTM is 125.001. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	212.010	MRQ	226.957	-14.947
MRQ	226.957	TTM	125.001	+101.956
TTM	125.001	YOY	-5,008.300	+5,133.302
TTM	125.001	5Y	-950.661	+1,075.662
5Y	-950.661	10Y	-544.008	-406.653

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	212.010	-2.315	+214.325
MRQ	226.957	-2.560	+229.517
TTM	125.001	-2.664	+127.665
YOY	-5,008.300	-4.122	-5,004.178
5Y	-950.661	-6.258	-944.403
10Y	-544.008	-6.108	-537.900

Measures how much money you pay for each share for every $1 in earnings Biomarin generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Biomarin to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Biomarin is 226.96. This means the investor is paying $226.96 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.56.
What is the trend?
The trend is important because it shows you how Biomarin is performing over time. The most recent quarter might be important if Biomarin released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Biomarin up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Biomarin

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 191,838 = EPS
PE ratio MRQ = 226.96

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biomarin Pharmaceutical Inc:

The EOD is -468.871. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -501.927. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -105.711. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-468.871	MRQ	-501.927	+33.056
MRQ	-501.927	TTM	-105.711	-396.216
TTM	-105.711	YOY	-10.738	-94.973
TTM	-105.711	5Y	-134.771	+29.060
5Y	-134.771	10Y	-156.187	+21.416

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-468.871	-3.067	-465.804
MRQ	-501.927	-3.251	-498.676
TTM	-105.711	-3.545	-102.166
YOY	-10.738	-5.595	-5.143
5Y	-134.771	-8.315	-126.456
10Y	-156.187	-8.708	-147.479

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Biomarin is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 3.74 means the investor is paying $3.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Biomarin Pharmaceutical Inc:

The EOD is 3.490. Based on the equity, the company is fair priced.
The MRQ is 3.736. Based on the equity, the company is fair priced.
The TTM is 3.695. Based on the equity, the company is fair priced.

Trends

Current period		Compared to		+/-
EOD	3.490	MRQ	3.736	-0.246
MRQ	3.736	TTM	3.695	+0.041
TTM	3.695	YOY	3.659	+0.036
TTM	3.695	5Y	4.207	-0.512
5Y	4.207	10Y	5.826	-1.620

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	3.490	1.905	+1.585
MRQ	3.736	2.111	+1.625
TTM	3.695	2.095	+1.600
YOY	3.659	2.836	+0.823
5Y	4.207	3.443	+0.764
10Y	5.826	3.794	+2.032

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Biomarin Pharmaceutical Inc.

3.1. Institutions holding Biomarin Pharmaceutical Inc

Institutions are holding 101.31% of the shares of Biomarin Pharmaceutical Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	PRIMECAP Management Company	9.7598	1.4056	18414374	7835	0.0426
2023-12-31	Vanguard Group Inc	9.5667	0.038	18050062	348852	1.9708
2023-12-31	BlackRock Inc	7.7814	0.0361	14681644	74457	0.5097
2023-12-31	Dodge & Cox	7.417	0.8564	13994063	-159440	-1.1265
2023-12-31	Capital Research Global Investors	5.7107	0.2556	10774641	4756671	79.0411
2023-12-31	State Street Corporation	3.5672	0.0316	6730515	271786	4.208
2023-12-31	Ameriprise Financial Inc	2.8723	0.1564	5419366	255417	4.9462
2023-12-31	Barclays PLC	2.8032	0.1871	5288893	-284264	-5.1006
2023-12-31	Viking Global Investors LP	2.5915	1.7268	4889454	673998	15.9887
2023-12-31	venBio Select Advisor LLC	2.279	5.7268	4300000	450000	11.6883
2023-12-31	Deutsche Bank AG	1.8032	0.1674	3402197	2003478	143.2366
2023-12-31	NORGES BANK	1.7815	0.0566	3361310	607293	22.0512
2023-12-31	Elliott Investment Management L.P.	1.5902	1.5456	3000338	3000338	0
2023-12-31	Geode Capital Management, LLC	1.5224	0.0289	2872432	109996	3.9818
2023-12-31	HHG PLC	1.4789	0.1605	2790343	-634196	-18.5192
2023-12-31	Bank of New York Mellon Corp	1.357	0.0501	2560239	165099	6.8931
2023-12-31	JPMorgan Chase & Co	1.2974	0.0227	2447792	-171040	-6.5312
2023-12-31	Bank of America Corp	1.2502	0.0229	2358865	-36356	-1.5179
2023-12-31	Nomura Holdings Inc	1.1305	0.5574	2132937	-707873	-24.918
2023-12-31	Parnassus Investments, LLC	0.9802	0.396	1849348	-489181	-20.9183
Total		68.5403	13.4285	129318813	+10242870	+7.9%

3.2. Funds holding Biomarin Pharmaceutical Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Dodge & Cox Stock I	4.7245	0.8514	8914025	0	0
2023-12-31	Vanguard PRIMECAP Inv	3.6183	0.9321	6826903	129565	1.9346
2023-12-31	Capital Group AMCAP Composite	3.1561	0.7146	5954810	1311467	28.244
2023-12-31	VA CollegeAmerica Amcap 529A	3.1561	0.7146	5954810	1311467	28.244
2024-02-29	Vanguard Total Stock Mkt Idx Inv	3.1295	0.0329	5904595	-13833	-0.2337
2023-12-31	Vanguard Capital Opportunity Inv	2.847	2.4667	5371580	3550	0.0661
2024-02-29	Vanguard Mid Cap Index Institutional	2.231	0.2268	4209278	-11121	-0.2635
2023-12-31	American Funds Growth Fund of Amer A	2.0236	0.1478	3817955	3245672	567.1446
2023-12-31	Capital Group Growth Fnd of Amer Comp	2.0236	0.1478	3817955	3245672	567.1446
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.4761	0.2355	2785118	5680	0.2044
2024-02-29	Aviva Investors GlConvtAbsRet I USD Acc	1.3927	0	2627730	-155316	-5.5808
2023-12-31	PRIMECAP Odyssey Aggressive Growth	1.0265	2.5983	1936710	-3640	-0.1876
2024-02-29	Vanguard Growth Index Investor	0.9278	0.068	1750622	14165	0.8157
2023-12-31	PRIMECAP Odyssey Growth	0.8914	2.3677	1681856	-24060	-1.4104
2024-03-28	iShares Biotechnology ETF	0.7359	1.5892	1388532	-2417	-0.1738
2024-02-29	Vanguard Mid-Cap Growth ETF	0.7162	0.4819	1351314	8020	0.597
2023-12-31	Janus Inst Mid Cap Growth CF	0.6988	0.6468	1318485	0	0
2023-12-31	Janus Henderson Enterprise D	0.6988	0.6456	1318485	0	0
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.6052	0.2358	1141826	25700	2.3026
2024-02-29	R-co Valor C EUR	0.5699	1.9871	1075325	0	0
Total		36.649	17.0906	69147914	+9090571	+13.1%

3.3. Insider Transactions

Insiders are holding 0.688% of the shares of Biomarin Pharmaceutical Inc.

Date	Owner	Type	Amount	Price
2024-03-28	George Eric Davis	SELL	24602	88.34
2024-03-05	Henry J Fuchs	SELL	35341	85.18
2024-03-05	Jean Jacques Bienaime	SELL	1000	85.51
2024-03-05	Jeffrey Robert Ajer	SELL	4000	87.07
2024-02-27	Jean Jacques Bienaime	SELL	1000	90.35
2024-02-09	Jean Jacques Bienaime	SELL	15000	88.28
2024-01-09	Jean Jacques Bienaime	SELL	10000	98.19
2023-12-21	Jean Jacques Bienaime	SELL	10000	93.99
2023-12-13	George Eric Davis	SELL	13764	95.3
2023-08-16	Jeffrey Robert Ajer	SELL	5000	90
2023-08-10	Henry J Fuchs	SELL	12000	90.43
2023-08-08	George Eric Davis	SELL	11000	89.42
2023-08-07	Jean Jacques Bienaime	SELL	4000	88.1
2023-05-10	Jean Jacques Bienaime	SELL	30000	94.85
2023-04-10	Jean Jacques Bienaime	SELL	10000	99.56

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Biomarin Pharmaceutical Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.196	0.353	-45%	0.440	-55%	0.504	-61%	0.468	-58%
Book Value Per Share	-	-	25.811	24.981	+3%	23.755	+9%	21.271	+21%	16.971	+52%
Current Ratio	-	-	25.115	9.337	+169%	5.030	+399%	5.220	+381%	4.654	+440%
Debt To Asset Ratio	-	-	0.276	0.275	+1%	0.273	+1%	0.300	-8%	0.329	-16%
Debt To Equity Ratio	-	-	0.382	0.379	+1%	0.375	+2%	0.431	-11%	0.497	-23%
Dividend Per Share	-	-	-	0.093	-100%	0.040	-100%	0.027	-100%	0.013	-100%
Eps	-	-	0.106	0.217	-51%	0.182	-42%	0.275	-61%	-0.012	+112%
Free Cash Flow Per Share	-	-	-0.048	0.068	-170%	0.062	-177%	0.030	-260%	-0.164	+241%
Free Cash Flow To Equity Per Share	-	-	0.008	0.045	-81%	0.038	-78%	0.049	-83%	0.105	-92%
Gross Profit Margin	-	-	-5.537	-2.483	-55%	129.078	-104%	25.435	-122%	13.384	-141%
Intrinsic Value_10Y_max	-	-	17.466	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-2.568	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	0.683	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.592	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	2.866	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.499	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	6.029	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-2.093	-	-	-	-	-	-	-	-
Market Cap	16994047320.000	-9%	18497019960.000	17803572940.000	+4%	16545358620.000	+12%	16551301598.000	+12%	16852531576.000	+10%
Net Profit Margin	-	-	0.032	0.070	-55%	0.068	-53%	0.105	-70%	-0.054	+272%
Operating Margin	-	-	0.022	0.065	-66%	0.028	-20%	-0.010	+145%	-0.086	+492%
Operating Ratio	-	-	0.978	0.935	+5%	0.980	0%	1.020	-4%	1.104	-11%
Pb Ratio	3.490	-7%	3.736	3.695	+1%	3.659	+2%	4.207	-11%	5.826	-36%
Pe Ratio	212.010	-7%	226.957	125.001	+82%	-5008.300	+2307%	-950.661	+519%	-544.008	+340%
Price Per Share	90.070	-7%	96.420	92.205	+5%	87.058	+11%	86.984	+11%	88.950	+8%
Price To Free Cash Flow Ratio	-468.871	+7%	-501.927	-105.711	-79%	-10.738	-98%	-134.771	-73%	-156.187	-69%
Price To Total Gains Ratio	459.324	-7%	491.706	26.341	+1767%	-30.403	+106%	-81.317	+117%	37.701	+1204%
Quick Ratio	-	-	17.215	6.657	+159%	4.142	+316%	4.121	+318%	4.025	+328%
Return On Assets	-	-	0.003	0.006	-53%	0.006	-49%	0.009	-66%	-0.004	+239%
Return On Equity	-	-	0.004	0.009	-53%	0.008	-49%	0.013	-68%	-0.007	+271%
Total Gains Per Share	-	-	0.196	0.447	-56%	0.480	-59%	0.531	-63%	0.481	-59%
Usd Book Value	-	-	4951549000.000	4822579000.000	+3%	4516948000.000	+10%	4051474050.000	+22%	3221139600.000	+54%
Usd Book Value Change Per Share	-	-	0.196	0.353	-45%	0.440	-55%	0.504	-61%	0.468	-58%
Usd Book Value Per Share	-	-	25.811	24.981	+3%	23.755	+9%	21.271	+21%	16.971	+52%
Usd Dividend Per Share	-	-	-	0.093	-100%	0.040	-100%	0.027	-100%	0.013	-100%
Usd Eps	-	-	0.106	0.217	-51%	0.182	-42%	0.275	-61%	-0.012	+112%
Usd Free Cash Flow	-	-	-9213000.000	12912000.000	-171%	11090500.000	-183%	5701150.000	-262%	-30907425.000	+235%
Usd Free Cash Flow Per Share	-	-	-0.048	0.068	-170%	0.062	-177%	0.030	-260%	-0.164	+241%
Usd Free Cash Flow To Equity Per Share	-	-	0.008	0.045	-81%	0.038	-78%	0.049	-83%	0.105	-92%
Usd Market Cap	16994047320.000	-9%	18497019960.000	17803572940.000	+4%	16545358620.000	+12%	16551301598.000	+12%	16852531576.000	+10%
Usd Price Per Share	90.070	-7%	96.420	92.205	+5%	87.058	+11%	86.984	+11%	88.950	+8%
Usd Profit	-	-	20375000.000	41911250.000	-51%	35390250.000	-42%	54018900.000	-62%	-1546550.000	+108%
Usd Revenue	-	-	646207000.000	604928750.000	+7%	524009750.000	+23%	496326600.000	+30%	387247775.000	+67%
Usd Total Gains Per Share	-	-	0.196	0.447	-56%	0.480	-59%	0.531	-63%	0.481	-59%
	EOD	+3 -5	MRQ	TTM	+11 -25	YOY	+12 -24	5Y	+16 -20	10Y	+25 -11

4.2. Fundamental Score

Let's check the fundamental score of Biomarin Pharmaceutical Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	212.010
Price to Book Ratio (EOD)	Between	0-1	3.490
Net Profit Margin (MRQ)	Greater than	0	0.032
Operating Margin (MRQ)	Greater than	0	0.022
Quick Ratio (MRQ)	Greater than	1	17.215
Current Ratio (MRQ)	Greater than	1	25.115
Debt to Asset Ratio (MRQ)	Less than	1	0.276
Debt to Equity Ratio (MRQ)	Less than	1	0.382
Return on Equity (MRQ)	Greater than	0.15	0.004
Return on Assets (MRQ)	Greater than	0.05	0.003
Total			6/10 (60.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Biomarin Pharmaceutical Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	57.872
Ma 20	Greater than	Ma 50	88.352
Ma 50	Greater than	Ma 100	87.642
Ma 100	Greater than	Ma 200	90.637
Open	Greater than	Close	90.250
Total			4/5 (80.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2022-12-31		2023-03-31		2023-06-30		2023-09-30		2023-12-31
Net Debt		358,488	145,444	503,932	-113,319	390,613	-90,043	300,570	-754,340,598	-754,040,028

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	6,841,603
Total Liabilities	1,890,054
Total Stockholder Equity	4,951,549

	As reported
Total Liabilities	1,890,054
Total Stockholder Equity	+ 4,951,549
Total Assets	= 6,841,603

Assets

Total Assets	6,841,603
Total Current Assets	2,956,088
Long-term Assets	3,885,515

Total Current Assets

Total Current Assets (as reported)	2,956,088
Cash And Cash Equivalents	755,127,000
Short-term Investments	318,683
Net Receivables	633,704
Other Current Assets	141,391
Total Current Assets (calculated)	756,220,778
+/-	753,264,690

Long-term Assets

Long-term Assets (as reported)	3,885,515
Property Plant Equipment	1,066,133
Goodwill	196,199
Long Term Investments	611,135
Intangible Assets	294,701
Long-term Assets Other	171,538
Long-term Assets (calculated)	2,339,706
+/-	1,545,809

Liabilities & Shareholders' Equity

Total Current Liabilities	117,702
Long-term Liabilities	713,030
Total Stockholder Equity	4,951,549

Total Current Liabilities

Total Current Liabilities (as reported)	117,702
Short-term Debt	493,877
Short Long Term Debt	493,877
Accounts payable	683,147
Other Current Liabilities	683,147
Total Current Liabilities (calculated)	2,354,048
+/-	2,236,346

Long-term Liabilities

Long-term Liabilities (as reported)	713,030
Long term Debt	593,095
Capital Lease Obligations	8,779
Long-term Liabilities Other	119,935
Long-term Liabilities (calculated)	721,809
+/-	8,779

Total Stockholder Equity

Total Stockholder Equity (as reported)	4,951,549
Common Stock	189
Retained Earnings	-621,554
Accumulated Other Comprehensive Income	-28,788
Other Stockholders Equity	5,601,702
Total Stockholder Equity (calculated)	4,951,549
+/-	0

Other

Capital Stock	189
Cash and Short Term Investments	1,073,810
Common Stock Shares Outstanding	191,838
Current Deferred Revenue	-1,742,469
Liabilities and Stockholders Equity	6,841,603
Net Debt	-754,040,028
Net Invested Capital	6,038,521
Net Working Capital	1,779,064
Property Plant and Equipment Gross	1,933,222
Short Long Term Debt Total	1,086,972

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

2002-09-30

2002-06-30

2002-03-31

2001-12-31

2001-09-30

2001-06-30

2001-03-31

2000-12-31

2000-09-30

2000-06-30

2000-03-31

1999-12-31

1999-09-30

1999-06-30

1999-03-31

> Total Assets

26,800
51,400
112,500
103,549
94,490
86,090
83,324
76,933
65,443
98,321
90,402
171,811
171,811
141,973
127,469
110,616
183,117
306,385
284,446
256,340
239,296
347,416
312,230
232,966
180,933
167,247
208,842
195,303
488,229
468,714
467,072
463,436
449,764
781,639
791,056
815,279
827,702
854,555
859,038
906,695
900,283
844,437
869,357
917,163
966,205
985,516
1,244,533
1,262,623
1,264,146
1,280,392
1,295,076
1,303,681
1,297,085
1,532,527
1,567,376
1,601,643
1,598,293
1,601,520
1,620,530
2,249,217
2,340,728
2,345,685
2,440,433
2,490,453
3,658,686
3,648,689
3,624,853
3,729,368
3,666,993
3,087,304
3,842,238
4,023,690
3,938,607
4,019,965
4,580,697
4,633,125
4,596,717
4,624,679
4,695,254
4,427,128
4,435,398
4,393,384
4,558,128
4,690,039
4,722,841
5,302,110
6,158,090
5,848,020
5,805,053
5,898,496
5,977,475
6,003,325
6,062,707
6,145,841
6,264,040
6,375,074
6,433,695
6,563,172
6,758,163
6,841,603

6,841,603

6,758,163

6,563,172

6,433,695

6,375,074

6,264,040

6,145,841

6,062,707

6,003,325

5,977,475

5,898,496

5,805,053

5,848,020

6,158,090

5,302,110

4,722,841

4,690,039

4,558,128

4,393,384

4,435,398

4,427,128

4,695,254

4,624,679

4,596,717

4,633,125

4,580,697

4,019,965

3,938,607

4,023,690

3,842,238

3,087,304

3,666,993

3,729,368

3,624,853

3,648,689

3,658,686

2,490,453

2,440,433

2,345,685

2,340,728

2,249,217

1,620,530

1,601,520

1,598,293

1,601,643

1,567,376

1,532,527

1,297,085

1,303,681

1,295,076

1,280,392

1,264,146

1,262,623

1,244,533

985,516

966,205

917,163

869,357

844,437

900,283

906,695

859,038

854,555

827,702

815,279

791,056

781,639

449,764

463,436

467,072

468,714

488,229

195,303

208,842

167,247

180,933

232,966

312,230

347,416

239,296

256,340

284,446

306,385

183,117

110,616

127,469

141,973

171,811

90,402

98,321

65,443

76,933

83,324

86,090

94,490

103,549

112,500

51,400

26,800

> Total Current Assets

5,500
21,100
76,400
66,422
61,552
53,532
51,414
44,541
35,861
63,586
50,642
136,783
136,783
105,555
91,370
81,072
154,795
275,052
254,206
225,269
208,825
181,587
140,687
85,277
53,599
39,336
82,188
68,941
378,759
344,807
339,366
334,224
320,645
640,932
641,234
644,297
683,728
701,814
697,013
737,696
713,575
506,981
520,267
467,727
500,431
521,908
554,189
504,260
503,830
514,111
487,024
469,802
513,390
681,534
719,386
743,462
723,024
720,920
713,479
1,137,418
1,246,410
1,220,227
1,077,819
1,425,629
1,522,728
1,213,929
1,175,589
1,089,639
992,790
1,105,946
1,666,571
1,421,791
1,352,788
1,458,820
2,050,029
2,207,144
2,241,110
2,280,067
2,407,853
2,056,215
1,916,855
1,806,768
1,859,359
1,942,143
2,116,249
2,647,566
2,738,979
2,342,219
2,288,766
2,357,837
2,311,570
2,274,385
2,394,024
2,517,598
2,682,701
2,751,457
2,842,105
2,950,117
2,955,308
2,956,088

2,956,088

2,955,308

2,950,117

2,842,105

2,751,457

2,682,701

2,517,598

2,394,024

2,274,385

2,311,570

2,357,837

2,288,766

2,342,219

2,738,979

2,647,566

2,116,249

1,942,143

1,859,359

1,806,768

1,916,855

2,056,215

2,407,853

2,280,067

2,241,110

2,207,144

2,050,029

1,458,820

1,352,788

1,421,791

1,666,571

1,105,946

992,790

1,089,639

1,175,589

1,213,929

1,522,728

1,425,629

1,077,819

1,220,227

1,246,410

1,137,418

713,479

720,920

723,024

743,462

719,386

681,534

513,390

469,802

487,024

514,111

503,830

504,260

554,189

521,908

500,431

467,727

520,267

506,981

713,575

737,696

697,013

701,814

683,728

644,297

641,234

640,932

320,645

334,224

339,366

344,807

378,759

68,941

82,188

39,336

53,599

85,277

140,687

181,587

208,825

225,269

254,206

275,052

154,795

81,072

91,370

105,555

136,783

50,642

63,586

35,861

44,541

51,414

53,532

61,552

66,422

76,400

21,100

5,500

Cash And Cash Equivalents

3,600
17,200
32,600
23,413
40,675
10,609
16,098
16,530
19,722
18,967
7,230
12,528
12,528
19,363
32,405
33,638
125,835
221,772
187,978
121,406
96,199
48,247
34,981
13,081
11,246
17,111
56,213
38,092
341,689
285,990
191,782
89,162
98,331
205,010
291,825
228,343
319,990
252,209
271,217
222,900
214,579
200,050
191,778
167,171
108,963
115,779
127,539
88,079
90,782
112,956
71,254
46,272
82,586
177,757
181,330
180,527
154,380
175,445
181,565
568,781
639,778
584,717
398,005
875,486
900,570
440,664
376,346
397,040
270,453
305,969
707,349
408,330
348,234
354,864
431,399
598,028
473,980
427,411
882,184
493,982
364,369
307,577
423,220
437,446
476,632
818,900
1,015,675
649,158
667,313
641,533
617,143
587,276
605,440
619,802
761,515
724,531
580,074
694,381
785,414
755,127,000

755,127,000

785,414

694,381

580,074

724,531

761,515

619,802

605,440

587,276

617,143

641,533

667,313

649,158

1,015,675

818,900

476,632

437,446

423,220

307,577

364,369

493,982

882,184

427,411

473,980

598,028

431,399

354,864

348,234

408,330

707,349

305,969

270,453

397,040

376,346

440,664

900,570

875,486

398,005

584,717

639,778

568,781

181,565

175,445

154,380

180,527

181,330

177,757

82,586

46,272

71,254

112,956

90,782

88,079

127,539

115,779

108,963

167,171

191,778

200,050

214,579

222,900

271,217

252,209

319,990

228,343

291,825

205,010

98,331

89,162

191,782

285,990

341,689

38,092

56,213

17,111

11,246

13,081

34,981

48,247

96,199

121,406

187,978

221,772

125,835

33,638

32,405

19,363

12,528

7,230

18,967

19,722

16,530

16,098

10,609

40,675

23,413

32,600

17,200

3,600

Short-term Investments

300
300
39,600
39,573
14,999
38,803
31,407
23,671
10,044
40,918
36,675
118,569
118,569
81,195
54,063
40,340
22,743
44,588
53,911
84,951
94,999
80,549
51,570
35,734
18,513
9,574
9,700
9,700
6,000
19,910
102,118
199,685
174,976
382,700
294,861
357,251
254,772
323,448
291,752
336,892
337,290
146,341
171,566
133,506
214,679
221,894
224,428
186,033
161,799
145,964
153,120
148,820
150,393
224,829
245,125
270,211
247,502
225,116
198,086
215,942
247,703
251,901
268,368
69,706
108,119
240,889
241,984
195,579
186,400
197,318
327,499
381,347
329,821
372,912
825,700
797,940
908,815
935,662
561,192
590,326
530,485
423,526
297,572
316,361
381,764
561,472
489,998
416,228
420,178
481,864
462,333
426,599
450,798
489,945
512,253
567,006
572,017
476,577
340,431
318,683

318,683

340,431

476,577

572,017

567,006

512,253

489,945

450,798

426,599

462,333

481,864

420,178

416,228

489,998

561,472

381,764

316,361

297,572

423,526

530,485

590,326

561,192

935,662

908,815

797,940

825,700

372,912

329,821

381,347

327,499

197,318

186,400

195,579

241,984

240,889

108,119

69,706

268,368

251,901

247,703

215,942

198,086

225,116

247,502

270,211

245,125

224,829

150,393

148,820

153,120

145,964

161,799

186,033

224,428

221,894

214,679

133,506

171,566

146,341

337,290

336,892

291,752

323,448

254,772

357,251

294,861

382,700

174,976

199,685

102,118

19,910

6,000

9,700

9,574

18,513

35,734

51,570

80,549

94,999

84,951

53,911

44,588

22,743

40,340

54,063

81,195

118,569

36,675

40,918

10,044

23,671

31,407

38,803

14,999

39,573

39,600

300

Net Receivables

900
1,500
400
2,466
5,006
3,018
2,960
2,934
754
2,231
4,851
3,096
3,096
2,135
2,332
0
0
0
0
0
0
4,612
119
4,047
1,831
2,871
5,328
5,860
7,493
10,946
13,000
14,670
14,525
15,900
15,968
16,976
47,253
52,156
51,135
54,298
61,355
81,346
68,378
73,540
82,606
77,682
78,734
93,884
106,198
106,606
107,057
110,932
105,828
100,750
117,290
109,066
120,345
115,063
124,745
117,822
110,462
122,282
121,395
144,472
175,738
186,083
148,949
164,959
180,751
214,158
215,894
215,280
230,250
238,338
251,891
261,365
318,394
363,566
384,343
342,633
393,429
377,150
402,970
377,404
396,384
381,215
411,712
448,351
396,097
424,419
374,937
373,399
430,147
466,507
419,622
461,316
597,913
610,222
572,498
633,704

633,704

572,498

610,222

597,913

461,316

419,622

466,507

430,147

373,399

374,937

424,419

396,097

448,351

411,712

381,215

396,384

377,404

402,970

377,150

393,429

342,633

384,343

363,566

318,394

261,365

251,891

238,338

230,250

215,280

215,894

214,158

180,751

164,959

148,949

186,083

175,738

144,472

121,395

122,282

110,462

117,822

124,745

115,063

120,345

109,066

117,290

100,750

105,828

110,932

107,057

106,606

106,198

93,884

78,734

77,682

82,606

73,540

68,378

81,346

61,355

54,298

51,135

52,156

47,253

16,976

15,968

15,900

14,525

14,670

13,000

10,946

7,493

5,860

5,328

2,871

1,831

4,047

119

4,612

2,332

2,135

3,096

4,851

2,231

754

2,934

2,960

3,018

5,006

2,466

400

1,500

900

Inventory

100
800
900
676
647
495
446
436
439
480
525
0
0
0
0
0
0
0
0
0
0
2,074
3,090
2,316
2,439
3,386
7,720
10,898
18,137
24,247
25,762
25,075
27,438
30,714
31,551
32,445
54,736
61,802
68,094
73,162
76,423
72,836
75,441
78,662
79,761
83,778
91,741
109,698
110,067
112,299
115,628
130,118
124,064
120,125
120,825
128,695
135,822
142,296
148,684
162,605
176,893
193,498
204,444
199,452
222,833
237,532
262,100
271,683
296,979
326,556
347,420
355,126
384,143
429,831
457,393
475,775
468,161
473,356
508,482
530,871
534,696
578,736
609,049
680,275
705,652
743,852
700,847
698,548
713,929
710,975
749,406
776,669
786,356
802,315
839,460
894,083
918,921
975,546
1,032,159
1,107,183

1,107,183

1,032,159

975,546

918,921

894,083

839,460

802,315

786,356

776,669

749,406

710,975

713,929

698,548

700,847

743,852

705,652

680,275

609,049

578,736

534,696

530,871

508,482

473,356

468,161

475,775

457,393

429,831

384,143

355,126

347,420

326,556

296,979

271,683

262,100

237,532

222,833

199,452

204,444

193,498

176,893

162,605

148,684

142,296

135,822

128,695

120,825

120,125

124,064

130,118

115,628

112,299

110,067

109,698

91,741

83,778

79,761

78,662

75,441

72,836

76,423

73,162

68,094

61,802

54,736

32,445

31,551

30,714

27,438

25,075

25,762

24,247

18,137

10,898

7,720

3,386

2,439

2,316

3,090

2,074

525

480

439

436

446

495

647

676

900

800

100

Other Current Assets

600
1,300
2,900
294
225
607
503
970
3,386
990
1,361
2,590
2,590
2,862
2,570
7,094
6,217
8,692
12,317
18,912
17,627
20,981
25,729
4,801
6,640
6,275
3,227
4,391
5,440
3,714
6,704
5,632
5,375
6,608
7,029
9,282
6,977
12,199
14,815
50,444
23,928
239
13,104
14,848
14,422
22,775
31,747
235
34,984
36,286
39,965
4,994
50,519
58,073
54,816
25,509
35,501
33,526
28,161
41,707
41,013
37,268
56,458
105,310
84,265
77,558
115,330
60,378
58,207
61,945
68,409
61,708
60,340
62,875
83,646
74,036
71,760
80,072
71,652
98,403
93,876
119,779
126,548
130,657
155,817
142,127
120,747
129,934
91,249
99,046
107,751
110,442
121,283
139,029
149,851
104,521
173,180
193,391
224,806
141,391

141,391

224,806

193,391

173,180

104,521

149,851

139,029

121,283

110,442

107,751

99,046

91,249

129,934

120,747

142,127

155,817

130,657

126,548

119,779

93,876

98,403

71,652

80,072

71,760

74,036

83,646

62,875

60,340

61,708

68,409

61,945

58,207

60,378

115,330

77,558

84,265

105,310

56,458

37,268

41,013

41,707

28,161

33,526

35,501

25,509

54,816

58,073

50,519

4,994

39,965

36,286

34,984

235

31,747

22,775

14,422

14,848

13,104

239

23,928

50,444

14,815

12,199

6,977

9,282

7,029

6,608

5,375

5,632

6,704

3,714

5,440

4,391

3,227

6,275

6,640

4,801

25,729

20,981

17,627

18,912

12,317

8,692

6,217

7,094

2,570

2,862

2,590

1,361

990

3,386

970

503

607

225

294

2,900

1,300

600

> Long-term Assets

21,300
30,300
36,100
37,127
32,938
32,558
31,910
32,392
29,582
34,735
39,760
35,028
35,028
36,418
36,099
29,544
28,322
31,333
30,240
31,071
30,471
165,829
171,543
147,689
127,334
127,911
126,654
126,362
109,470
123,907
127,706
129,212
129,119
140,707
149,822
170,982
143,974
152,741
162,025
168,999
186,708
337,456
349,090
449,436
465,774
463,608
690,344
758,363
760,316
766,281
808,052
833,879
783,695
850,993
847,990
858,181
875,269
880,600
907,051
1,111,799
1,094,318
1,125,458
1,362,614
1,064,824
2,135,958
2,434,760
2,449,264
2,639,729
2,674,203
1,981,358
2,175,667
2,601,899
2,585,819
2,561,145
2,530,668
2,425,981
2,355,607
2,344,612
2,287,401
2,370,913
2,518,543
2,586,616
2,698,769
2,747,896
2,606,592
2,654,544
3,419,111
3,505,801
3,516,287
3,540,659
3,665,905
3,728,940
3,668,683
3,628,243
3,581,339
3,623,617
3,591,590
3,613,055
3,802,855
3,885,515

3,885,515

3,802,855

3,613,055

3,591,590

3,623,617

3,581,339

3,628,243

3,668,683

3,728,940

3,665,905

3,540,659

3,516,287

3,505,801

3,419,111

2,654,544

2,606,592

2,747,896

2,698,769

2,586,616

2,518,543

2,370,913

2,287,401

2,344,612

2,355,607

2,425,981

2,530,668

2,561,145

2,585,819

2,601,899

2,175,667

1,981,358

2,674,203

2,639,729

2,449,264

2,434,760

2,135,958

1,064,824

1,362,614

1,125,458

1,094,318

1,111,799

907,051

880,600

875,269

858,181

847,990

850,993

783,695

833,879

808,052

766,281

760,316

758,363

690,344

463,608

465,774

449,436

349,090

337,456

186,708

168,999

162,025

152,741

143,974

170,982

149,822

140,707

129,119

129,212

127,706

123,907

109,470

126,362

126,654

127,911

127,334

147,689

171,543

165,829

30,471

31,071

30,240

31,333

28,322

29,544

36,099

36,418

35,028

39,760

34,735

29,582

32,392

31,910

32,558

32,938

37,127

36,100

30,300

21,300

Property Plant Equipment

8,600
17,000
22,900
25,093
20,743
20,387
20,031
20,715
19,983
22,921
27,996
32,560
32,560
32,704
30,994
28,206
26,338
24,900
23,993
25,154
24,447
27,000
35,620
42,501
41,179
39,556
37,799
37,321
36,251
51,615
52,469
55,466
56,487
58,780
66,249
76,818
95,732
105,199
110,716
124,979
142,252
159,789
182,099
199,141
203,949
212,620
213,755
221,866
217,884
216,496
266,190
268,971
264,317
267,374
273,724
284,473
281,865
282,002
285,664
319,316
437,066
469,862
486,741
523,516
538,117
568,051
604,513
704,207
716,916
724,494
729,836
798,768
824,013
851,097
878,624
896,700
895,392
900,480
924,033
948,682
951,890
962,970
969,300
1,010,868
1,009,972
1,010,917
1,015,062
1,032,471
1,022,474
1,026,579
1,024,787
1,035,461
1,039,544
1,049,464
1,051,821
1,073,366
1,068,142
1,067,278
1,067,156
1,066,133

1,066,133

1,067,156

1,067,278

1,068,142

1,073,366

1,051,821

1,049,464

1,039,544

1,035,461

1,024,787

1,026,579

1,022,474

1,032,471

1,015,062

1,010,917

1,009,972

1,010,868

969,300

962,970

951,890

948,682

924,033

900,480

895,392

896,700

878,624

851,097

824,013

798,768

729,836

724,494

716,916

704,207

604,513

568,051

538,117

523,516

486,741

469,862

437,066

319,316

285,664

282,002

281,865

284,473

273,724

267,374

264,317

268,971

266,190

216,496

217,884

221,866

213,755

212,620

203,949

199,141

182,099

159,789

142,252

124,979

110,716

105,199

95,732

76,818

66,249

58,780

56,487

55,466

52,469

51,615

36,251

37,321

37,799

39,556

41,179

42,501

35,620

27,000

24,447

25,154

23,993

24,900

26,338

28,206

30,994

32,704

32,560

27,996

22,921

19,983

20,715

20,031

20,387

20,743

25,093

22,900

17,000

8,600

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,250
45,053
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
21,262
23,722
40,360
40,360
53,364
53,364
53,055
53,055
51,543
51,543
51,543
51,543
51,543
51,543
54,975
54,975
54,258
54,258
54,258
54,258
54,258
54,258
202,392
202,392
202,392
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
197,039
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199

196,199

197,039

202,392

54,258

54,975

51,543

53,055

53,364

40,360

23,722

21,262

45,053

32,250

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
118,085
90,116
129,253
142,511
154,327
146,808
94,944
55,833
123,155
107,589
117,073
124,498
124,906
148,625
268,516
251,928
244,588
449,143
98,895
224,810
509,627
514,381
443,708
314,404
201,620
362,956
572,711
533,628
482,036
416,304
385,785
313,599
279,988
204,883
235,864
320,000
374,965
431,804
411,978
290,796
323,058
265,122
285,473
321,127
350,237
466,618
507,793
462,827
412,503
372,302
333,835
340,635
385,777
548,002
611,135

611,135

548,002

385,777

340,635

333,835

372,302

412,503

462,827

507,793

466,618

350,237

321,127

285,473

265,122

323,058

290,796

411,978

431,804

374,965

320,000

235,864

204,883

279,988

313,599

385,785

416,304

482,036

533,628

572,711

362,956

201,620

314,404

443,708

514,381

509,627

224,810

98,895

449,143

244,588

251,928

268,516

148,625

124,906

124,498

117,073

107,589

123,155

55,833

94,944

146,808

154,327

142,511

129,253

90,116

118,085

Intangible Assets

11,400
11,900
11,600
11,462
11,159
10,856
10,345
9,862
9,333
8,868
8,314
0
0
0
0
0
0
0
0
0
0
133,090
131,373
61,504
37,427
37,140
36,854
36,558
14,934
13,841
12,748
11,655
10,563
9,470
8,377
9,596
8,420
7,244
6,068
7,626
6,316
4,391
4,194
40,977
77,416
77,985
104,604
103,648
102,692
101,736
100,780
180,277
170,914
168,267
165,624
162,980
172,016
168,434
165,791
163,147
165,397
163,045
159,949
156,578
926,896
923,861
920,943
683,996
1,177,232
568,966
561,387
553,780
546,172
538,565
530,957
517,510
509,902
502,295
494,687
491,808
485,981
476,632
462,849
456,580
443,717
433,381
427,172
417,271
405,903
394,298
388,487
388,652
374,251
369,368
354,024
338,569
325,989
310,343
302,476
294,701

294,701

302,476

310,343

325,989

338,569

354,024

369,368

374,251

388,652

388,487

394,298

405,903

417,271

427,172

433,381

443,717

456,580

462,849

476,632

485,981

491,808

494,687

502,295

509,902

517,510

530,957

538,565

546,172

553,780

561,387

568,966

1,177,232

683,996

920,943

923,861

926,896

156,578

159,949

163,045

165,397

163,147

165,791

168,434

172,016

162,980

165,624

168,267

170,914

180,277

100,780

101,736

102,692

103,648

104,604

77,985

77,416

40,977

4,194

4,391

6,316

7,626

6,068

7,244

8,420

9,596

8,377

9,470

10,563

11,655

12,748

13,841

14,934

36,558

36,854

37,140

37,427

61,504

131,373

133,090

8,314

8,868

9,333

9,862

10,345

10,856

11,159

11,462

11,600

11,900

11,400

Long-term Assets Other

1,300
1,400
1,600
572
1,036
1,315
1,534
1,815
266
2,946
3,450
2,468
2,468
3,714
5,105
1,338
1,984
6,433
6,247
5,917
6,024
5,739
4,550
43,684
48,728
51,215
52,001
52,483
37,023
37,189
41,227
40,829
40,807
51,195
53,934
63,306
18,560
19,036
23,979
12,584
12,500
12,689
12,578
15,306
14,112
14,558
12,413
14,215
12,227
12,267
13,559
15,495
19,849
20,061
19,739
16,611
15,158
14,883
14,010
143,171
41,545
46,562
61,532
65,281
80,332
58,284
60,790
408,644
25,400
23,057
36,443
32,815
26,580
21,447
22,985
29,852
32,666
39,430
37,565
36,568
96,300
99,456
112,646
122,009
125,918
135,852
119,009
142,237
141,198
141,663
144,705
151,760
149,186
151,797
151,788
176,236
150,057
144,168
165,069
171,538

171,538

165,069

144,168

150,057

176,236

151,788

151,797

149,186

151,760

144,705

141,663

141,198

142,237

119,009

135,852

125,918

122,009

112,646

99,456

96,300

36,568

37,565

39,430

32,666

29,852

22,985

21,447

26,580

32,815

36,443

23,057

25,400

408,644

60,790

58,284

80,332

65,281

61,532

46,562

41,545

143,171

14,010

14,883

15,158

16,611

19,739

20,061

19,849

15,495

13,559

12,267

12,227

14,215

12,413

14,558

14,112

15,306

12,578

12,689

12,500

12,584

23,979

19,036

18,560

63,306

53,934

51,195

40,807

40,829

41,227

37,189

37,023

52,483

52,001

51,215

48,728

43,684

4,550

5,739

6,024

5,917

6,247

6,433

1,984

1,338

5,105

3,714

2,468

3,450

2,946

266

1,815

1,534

1,315

1,036

572

1,600

1,400

1,300

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236,017
231,947
228,400
229,172
222,649
221,239
220,593
229,771
225,501
226,757
235,400
238,703
150,391
144,124
147,143
150,991
166,296
163,411
172,545
146,245
220,191
243,212
266,182
288,006
446,786
458,387
470,961
484,759
399,095
407,009
425,380
429,194
460,952
467,333
475,554
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

475,554

467,333

460,952

429,194

425,380

407,009

399,095

484,759

470,961

458,387

446,786

288,006

266,182

243,212

220,191

146,245

172,545

163,411

166,296

150,991

147,143

144,124

150,391

238,703

235,400

226,757

225,501

229,771

220,593

221,239

222,649

229,172

228,400

231,947

236,017

> Total Liabilities

1,700
34,000
5,700
5,172
4,759
2,894
3,672
6,939
3,684
5,321
6,236
12,263
12,263
11,194
11,259
12,073
17,215
143,948
142,483
138,487
140,524
304,226
298,067
300,944
271,168
277,689
274,221
272,765
442,224
419,827
344,955
345,634
285,050
614,037
616,511
627,553
618,536
628,528
621,137
630,020
626,343
561,003
565,504
594,978
620,965
622,554
658,869
545,366
543,306
548,087
520,537
530,633
525,135
532,101
552,182
585,880
348,141
343,262
344,044
908,176
880,607
883,716
931,991
962,559
1,233,231
1,291,732
1,332,213
1,328,521
1,376,757
1,169,728
1,196,430
1,257,415
1,169,520
1,224,386
1,767,135
1,824,462
1,789,714
1,739,575
1,780,309
1,459,188
1,498,771
1,432,430
1,483,723
1,567,658
1,482,879
2,065,431
2,104,197
1,742,018
1,643,043
1,656,925
1,711,326
1,732,585
1,671,392
1,641,034
1,695,526
1,771,918
1,774,652
1,780,345
1,861,266
1,890,054

1,890,054

1,861,266

1,780,345

1,774,652

1,771,918

1,695,526

1,641,034

1,671,392

1,732,585

1,711,326

1,656,925

1,643,043

1,742,018

2,104,197

2,065,431

1,482,879

1,567,658

1,483,723

1,432,430

1,498,771

1,459,188

1,780,309

1,739,575

1,789,714

1,824,462

1,767,135

1,224,386

1,169,520

1,257,415

1,196,430

1,169,728

1,376,757

1,328,521

1,332,213

1,291,732

1,233,231

962,559

931,991

883,716

880,607

908,176

344,044

343,262

348,141

585,880

552,182

532,101

525,135

530,633

520,537

548,087

543,306

545,366

658,869

622,554

620,965

594,978

565,504

561,003

626,343

630,020

621,137

628,528

618,536

627,553

616,511

614,037

285,050

345,634

344,955

419,827

442,224

272,765

274,221

277,689

271,168

300,944

298,067

304,226

140,524

138,487

142,483

143,948

17,215

12,073

11,259

11,194

12,263

6,236

5,321

3,684

6,939

3,672

2,894

4,759

5,172

5,700

34,000

1,700

> Total Current Liabilities

1,600
7,900
5,600
5,087
4,682
2,826
3,609
6,883
3,637
5,123
6,090
8,302
8,302
7,731
8,347
6,847
12,719
15,251
16,243
12,815
15,161
81,270
75,715
70,054
50,695
43,702
44,224
40,367
56,887
38,004
43,229
46,045
38,829
44,543
49,062
61,543
53,311
63,423
120,735
130,081
126,314
60,033
64,070
78,154
78,699
83,930
92,097
83,844
75,986
82,035
83,254
94,125
119,814
119,997
134,929
170,433
144,008
142,241
167,633
183,271
156,038
166,720
206,550
235,739
305,506
347,704
390,491
445,457
388,011
364,580
377,335
439,310
340,206
374,303
417,529
816,518
773,471
804,950
838,660
523,241
500,986
439,428
493,745
932,503
820,470
813,302
854,693
492,548
430,035
443,344
514,898
539,822
490,418
464,727
521,020
588,884
598,231
597,231
1,163,223
117,702

117,702

1,163,223

597,231

598,231

588,884

521,020

464,727

490,418

539,822

514,898

443,344

430,035

492,548

854,693

813,302

820,470

932,503

493,745

439,428

500,986

523,241

838,660

804,950

773,471

816,518

417,529

374,303

340,206

439,310

377,335

364,580

388,011

445,457

390,491

347,704

305,506

235,739

206,550

166,720

156,038

183,271

167,633

142,241

144,008

170,433

134,929

119,997

119,814

94,125

83,254

82,035

75,986

83,844

92,097

83,930

78,699

78,154

64,070

60,033

126,314

130,081

120,735

63,423

53,311

61,543

49,062

44,543

38,829

46,045

43,229

38,004

56,887

40,367

44,224

43,702

50,695

70,054

75,715

81,270

15,161

12,815

16,243

15,251

12,719

6,847

8,347

7,731

8,302

6,090

5,123

3,637

6,883

3,609

2,826

4,682

5,087

5,600

7,900

1,600

Short-term Debt

0
0
0
26
26
29
28
27
29
98
95
1,591
1,591
0
0
0
0
0
0
118,396
0
58,228
48,747
42,805
25,056
12,145
11,696
11,337
27,048
6,705
6,787
6,787
6,786
6,785
6,549
6,309
6,065
5,816
45,193
70,741
70,317
0
0
0
0
0
0
75,620
0
0
0
0
23,455
23,440
23,440
23,365
0
0
0
0
0
0
0
642,902
0
0
0
662,286
0
24,420
22,460
22,478
22,495
676,205
-17,430
360,949
365,326
369,752
374,230
0
9,210
10,165
10,225
361,882
365,964
370,100
374,290
11,754
11,227
11,024
9,659
10,464
10,829
10,611
9,226
10,375
9,251
8,294
493,398
493,877

493,877

493,398

8,294

9,251

10,375

9,226

10,611

10,829

10,464

9,659

11,024

11,227

11,754

374,290

370,100

365,964

361,882

10,225

10,165

9,210

374,230

369,752

365,326

360,949

-17,430

676,205

22,495

22,478

22,460

24,420

662,286

642,902

23,365

23,440

23,455

75,620

70,317

70,741

45,193

5,816

6,065

6,309

6,549

6,785

6,786

6,787

6,705

27,048

11,337

11,696

12,145

25,056

42,805

48,747

58,228

118,396

1,591

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
642,902
0
0
0
662,286
0
72,238
71,206
22,478
67,759
676,205
1,166,036
360,949
365,326
369,752
374,230
0
6,347
0
0
361,882
365,964
370,100
374,290
0
0
0
0
0
0
0
0
0
0
0
493,398
493,877

493,877

493,398

374,290

370,100

365,964

361,882

6,347

374,230

369,752

365,326

360,949

1,166,036

676,205

67,759

22,478

71,206

72,238

662,286

642,902

Accounts payable

800
6,000
5,000
3,095
1,367
990
1,792
4,747
1,616
3,049
3,923
4,284
4,284
2,014
763
3,930
9,532
12,123
13,399
10,098
2,299
840
466
946
2,470
2,324
539
484
440
231
1,498
2,285
748
754
1,313
1,169
2,326
2,847
2,029
58,851
5,178
31,012
2,076
7,567
3,276
9,708
7,184
4,956
5,274
7,252
7,107
12,239
12,439
12,501
11,459
147,068
144,008
142,241
167,633
95,302
156,038
166,720
206,550
235,739
230,212
256,330
296,200
392,511
290,562
292,342
306,129
370,505
135,604
158,229
364,920
401,921
346,538
358,732
378,226
437,290
412,830
429,502
483,745
570,621
454,506
443,202
218,021
191,429
399,225
411,132
203,321
193,003
187,810
199,251
207,165
231,238
264,778
277,944
301,369
683,147

683,147

301,369

277,944

264,778

231,238

207,165

199,251

187,810

193,003

203,321

411,132

399,225

191,429

218,021

443,202

454,506

570,621

483,745

429,502

412,830

437,290

378,226

358,732

346,538

401,921

364,920

158,229

135,604

370,505

306,129

292,342

290,562

392,511

296,200

256,330

230,212

235,739

206,550

166,720

156,038

95,302

167,633

142,241

144,008

147,068

11,459

12,501

12,439

12,239

7,107

7,252

5,274

4,956

7,184

9,708

3,276

7,567

2,076

31,012

5,178

58,851

2,029

2,847

2,326

1,169

1,313

754

748

2,285

1,498

231

440

484

539

2,324

2,470

946

466

840

2,299

10,098

13,399

12,123

9,532

3,930

763

2,014

4,284

3,923

3,049

1,616

4,747

1,792

990

1,367

3,095

5,000

6,000

800

Other Current Liabilities

800
1,900
600
1,966
3,289
1,807
1,789
2,109
1,992
1,976
2,072
2,427
229
5,717
7,584
2,917
3,187
3,128
2,844
2,717
12,862
9,821
7,843
1,903
2,286
19,391
22,397
20,450
19,506
22,842
27,702
29,881
24,141
29,850
34,561
48,738
40,041
51,524
72,070
182
50,699
28,092
61,845
78,068
75,265
74,222
84,913
3,056
70,712
74,783
76,147
81,886
79,627
82,614
98,946
77,847
72,195
69,926
89,095
87,969
72,811
62,934
86,093
98,991
75,294
91,374
94,291
52,946
97,449
47,818
48,746
46,327
45,264
216,074
52,609
53,648
61,607
76,466
86,204
85,951
88,156
9,926
10,000
-13,037
-7,889
-5,350
259,142
289,213
30,810
32,212
48,187
329,399
291,473
254,560
304,214
346,560
324,202
597,231
669,825
683,147

683,147

669,825

597,231

324,202

346,560

304,214

254,560

291,473

329,399

48,187

32,212

30,810

289,213

259,142

-5,350

-7,889

-13,037

10,000

9,926

88,156

85,951

86,204

76,466

61,607

53,648

52,609

216,074

45,264

46,327

48,746

47,818

97,449

52,946

94,291

91,374

75,294

98,991

86,093

62,934

72,811

87,969

89,095

69,926

72,195

77,847

98,946

82,614

79,627

81,886

76,147

74,783

70,712

3,056

84,913

74,222

75,265

78,068

61,845

28,092

50,699

182

72,070

51,524

40,041

48,738

34,561

29,850

24,141

29,881

27,702

22,842

19,506

20,450

22,397

19,391

2,286

1,903

7,843

9,821

12,862

2,717

2,844

3,128

3,187

2,917

7,584

5,717

229

2,427

2,072

1,976

1,992

2,109

1,789

1,807

3,289

1,966

600

1,900

800

> Long-term Liabilities

100
26,100
100
85
77
68
63
56
47
198
146
3,961
3,961
3,463
2,912
5,226
4,496
128,697
126,240
125,672
125,363
222,956
222,352
230,890
220,473
233,987
229,997
232,398
385,337
381,823
301,726
299,589
246,221
569,494
567,449
566,010
565,225
565,105
500,402
499,939
500,029
500,970
501,434
516,824
542,266
538,624
566,772
461,522
467,320
466,052
437,283
436,508
405,321
412,104
417,253
415,447
204,133
201,021
176,411
724,905
724,569
716,996
725,441
726,820
927,725
944,028
941,722
883,064
988,746
805,148
819,095
818,105
829,314
850,083
1,349,606
1,007,944
1,016,243
934,625
941,649
935,947
997,785
993,002
989,978
635,155
662,409
1,252,129
1,249,504
1,249,470
1,213,008
1,213,581
1,196,428
1,192,763
1,180,974
1,176,307
1,174,506
1,183,034
1,176,421
1,183,114
698,043
713,030

713,030

698,043

1,183,114

1,176,421

1,183,034

1,174,506

1,176,307

1,180,974

1,192,763

1,196,428

1,213,581

1,213,008

1,249,470

1,249,504

1,252,129

662,409

635,155

989,978

993,002

997,785

935,947

941,649

934,625

1,016,243

1,007,944

1,349,606

850,083

829,314

818,105

819,095

805,148

988,746

883,064

941,722

944,028

927,725

726,820

725,441

716,996

724,569

724,905

176,411

201,021

204,133

415,447

417,253

412,104

405,321

436,508

437,283

466,052

467,320

461,522

566,772

538,624

542,266

516,824

501,434

500,970

500,029

499,939

500,402

565,105

565,225

566,010

567,449

569,494

246,221

299,589

301,726

381,823

385,337

232,398

229,997

233,987

220,473

230,890

222,352

222,956

125,363

125,672

126,240

128,697

4,496

5,226

2,912

3,463

3,961

146

198

100

26,100

100

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
497,083
497,083
377,521
377,521
377,520
348,339
348,329
324,872
324,865
324,861
324,859
109,849
109,822
78,310
655,566
661,419
650,872
656,884
657,976
655,491
661,492
667,793
662,286
668,009
645,685
653,178
660,761
668,437
676,205
1,166,036
813,521
817,672
821,871
826,119
830,417
834,766
839,165
853,160
486,238
486,713
1,073,202
1,074,164
1,075,145
1,076,127
1,077,110
1,078,093
1,079,077
1,080,061
1,081,047
1,082,033
0
1,084,006
1,084,994
0
0

1,084,994

1,084,006

1,082,033

1,081,047

1,080,061

1,079,077

1,078,093

1,077,110

1,076,127

1,075,145

1,074,164

1,073,202

486,713

486,238

853,160

839,165

834,766

830,417

826,119

821,871

817,672

813,521

1,166,036

676,205

668,437

660,761

653,178

645,685

668,009

662,286

667,793

661,492

655,491

657,976

656,884

650,872

661,419

655,566

78,310

109,822

109,849

324,859

324,861

324,865

324,872

348,329

348,339

377,520

377,521

497,083

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236,017
231,947
228,400
229,172
222,649
221,239
220,593
229,771
225,501
226,757
235,400
238,703
150,391
144,124
147,143
150,991
166,296
163,411
172,545
146,245
220,191
243,212
266,182
288,006
446,786
458,387
470,961
484,759
399,095
407,009
425,380
429,194
460,952
467,333
475,554
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

475,554

467,333

460,952

429,194

425,380

407,009

399,095

484,759

470,961

458,387

446,786

288,006

266,182

243,212

220,191

146,245

172,545

163,411

166,296

150,991

147,143

144,124

150,391

238,703

235,400

226,757

225,501

229,771

220,593

221,239

222,649

229,172

228,400

231,947

236,017

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,843
1,816
3,697
1,240
0
363
704
290
2,852
3,049
18,022
15,550
19,476
17,501
14,512
8,642
7,101
5,776
4,787
3,128
2,082
1,769
1,917
3,162
2,586
2,724
3,708
4,218
17,196
28,700
25,100
42,552
47,484
53,282
52,015
52,427
53,052
47,751
54,541
59,694
57,292
56,763
54,017
60,911
69,339
63,150
66,124
68,557
68,844
79,032
89,334
80,727
77,251
177,210
159,463
165,917
157,344
160,877
173,878
183,570
194,423
198,571
112,754
115,530
105,530
115,068
99,958
91,319
98,117
175,696
132,099
129,939
174,325
136,881
136,471
118,335
113,686
100,913
95,260
92,473
73,502
92,415
0
105,457
0

105,457

92,415

73,502

92,473

95,260

100,913

113,686

118,335

136,471

136,881

174,325

129,939

132,099

175,696

98,117

91,319

99,958

115,068

105,530

115,530

112,754

198,571

194,423

183,570

173,878

160,877

157,344

165,917

159,463

177,210

77,251

80,727

89,334

79,032

68,844

68,557

66,124

63,150

69,339

60,911

54,017

56,763

57,292

59,694

54,541

47,751

53,052

52,427

52,015

53,282

47,484

42,552

25,100

28,700

17,196

4,218

3,708

2,724

2,586

3,162

1,917

1,769

2,082

3,128

4,787

5,776

7,101

8,642

14,512

17,501

19,476

15,550

18,022

3,049

2,852

290

704

363

1,240

3,697

1,816

1,843

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,296
37,521
37,182
37,190
0
0
0
0
0
193,202
193,202
193,202
143,527
143,527
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

143,527

193,202

37,190

37,182

37,521

33,296

> Total Stockholder Equity

25,100
17,400
106,800
98,377
89,731
83,196
79,652
69,994
61,759
93,000
84,166
159,548
159,548
130,779
116,210
98,543
165,902
162,437
141,963
117,853
98,772
43,190
14,163
-67,978
-90,235
-110,442
-65,379
-77,462
46,005
48,887
122,117
117,802
164,714
167,602
174,545
187,726
209,166
226,027
237,901
276,675
273,940
283,434
303,853
322,185
345,240
362,962
585,664
717,257
720,840
732,305
774,539
773,048
771,950
1,000,426
1,015,194
1,015,763
1,250,152
1,258,258
1,276,486
1,341,041
1,460,121
1,461,969
1,508,442
1,527,894
2,425,455
2,356,957
2,292,640
2,400,847
2,290,236
1,917,576
2,645,808
2,766,275
2,769,087
2,795,579
2,813,562
2,808,663
2,807,003
2,885,104
2,914,945
2,967,940
2,936,627
2,960,954
3,074,405
3,122,381
3,239,962
3,236,679
4,053,893
4,106,002
4,162,010
4,241,571
4,266,149
4,270,740
4,391,315
4,504,807
4,568,514
4,603,156
4,659,043
4,782,827
4,896,897
4,951,549

4,951,549

4,896,897

4,782,827

4,659,043

4,603,156

4,568,514

4,504,807

4,391,315

4,270,740

4,266,149

4,241,571

4,162,010

4,106,002

4,053,893

3,236,679

3,239,962

3,122,381

3,074,405

2,960,954

2,936,627

2,967,940

2,914,945

2,885,104

2,807,003

2,808,663

2,813,562

2,795,579

2,769,087

2,766,275

2,645,808

1,917,576

2,290,236

2,400,847

2,292,640

2,356,957

2,425,455

1,527,894

1,508,442

1,461,969

1,460,121

1,341,041

1,276,486

1,258,258

1,250,152

1,015,763

1,015,194

1,000,426

771,950

773,048

774,539

732,305

720,840

717,257

585,664

362,962

345,240

322,185

303,853

283,434

273,940

276,675

237,901

226,027

209,166

187,726

174,545

167,602

164,714

117,802

122,117

48,887

46,005

-77,462

-65,379

-110,442

-90,235

-67,978

14,163

43,190

98,772

117,853

141,963

162,437

165,902

98,543

116,210

130,779

159,548

84,166

93,000

61,759

69,994

79,652

83,196

89,731

98,377

106,800

17,400

25,100

Common Stock

0
0
0
35
35
35
37
37
37
42
42
52
52
53
54
54
63
64
64
64
64
64
64
65
65
65
74
75
85
85
91
92
96
96
97
97
98
99
100
100
100
100
101
101
102
102
103
111
111
112
114
115
116
123
124
126
139
140
142
144
146
147
148
149
161
161
162
162
163
164
173
173
173
175
176
176
177
178
178
178
179
179
180
180
181
181
181
182
183
183
184
184
185
186
186
186
188
188
188
189

189

188

186

185

184

183

182

181

180

179

178

177

176

175

173

164

163

162

161

149

148

147

146

144

142

140

139

126

124

123

116

115

114

112

111

103

102

101

100

Retained Earnings

-621,554

-641,929

-682,307

-738,347

-789,199

-788,949

-777,227

-804,891

-925,689

-867,791

-831,297

-844,238

-861,609

-883,708

-1,668,511

-1,639,328

-1,720,709

-1,735,733

-1,790,769

-1,753,334

-1,694,134

-1,690,475

-1,677,855

-1,661,063

-1,637,548

-1,586,156

-1,573,629

-1,536,796

-1,520,506

-1,573,068

-1,530,271

-1,106,711

-1,021,569

-1,090,186

-999,260

-917,271

-849,770

-779,973

-787,418

-753,916

-715,801

-653,811

-600,791

-579,258

-539,448

-486,436

-481,079

-449,073

-425,101

-398,366

-380,713

-375,636

-371,265

-359,076

-576,410

-575,933

-577,084

-581,795

-588,436

-589,748

-576,596

-601,102

-601,931

-605,741

-607,427

-609,997

-604,781

-600,917

-591,624

-581,233

-574,197

-572,871

-563,091

-548,095

-532,619

-511,279

-488,821

-406,399

-376,921

-321,323

-301,378

-275,651

-254,360

-245,263

-225,580

-206,250

-189,133

-148,119

-113,197

-102,182

-90,213

-80,513

-70,119

-61,970

-54,884

-43,149

-34,100

-26,500

-19,600

Accumulated Other Comprehensive Income

-6,000
-5,800
-5,400
-5,101
-4,832
-4,510
-3,422
-3,470
-3,285
2,033
2,217
-14,248
2,385
3,046
3,996
5,031
5,043
5,128
5,195
5,057
5,102
-530
-260
-363
-235
-144
-16
-16
-15
-49
-24
-25
-5
-7
128
139
351
-575
-2,754
1,106
2,069
101
-704
933
4,405
10,224
-1,581
188
-5,787
-5,923
1,304
4,887
2,512
4,650
2,333
-202
1,155
2,441
11,473
5,018
7,275
9,941
19,189
27,466
43,819
32,461
25,184
21,033
47
4,528
2,158
12,816
5,020
-14,658
-21,434
-22,961
-28,545
-1,129
-2,160
5,271
19,794
17,439
37,003
20,164
34,127
30,050
10,385
-16,139
5,004
-939
10,239
14,432
-877
18,472
30,749
-3,867
-10,722
-18,617
6,257
-28,788

-28,788

6,257

-18,617

-10,722

-3,867

30,749

18,472

-877

14,432

10,239

-939

5,004

-16,139

10,385

30,050

34,127

20,164

37,003

17,439

19,794

5,271

-2,160

-1,129

-28,545

-22,961

-21,434

-14,658

5,020

12,816

2,158

4,528

21,033

25,184

32,461

43,819

27,466

19,189

9,941

7,275

5,018

11,473

2,441

1,155

-202

2,333

4,650

2,512

4,887

1,304

-5,923

-5,787

188

-1,581

10,224

4,405

933

-704

101

2,069

1,106

-2,754

-575

351

139

128

-7

-5

-25

-24

-49

-15

-16

-144

-235

-363

-260

-530

5,102

5,057

5,195

5,128

5,043

5,031

3,996

3,046

2,385

-14,248

2,217

2,033

-3,285

-3,470

-3,422

-4,510

-4,832

-5,101

-5,400

-5,800

-6,000

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
931,361
948,394
1,090,188
1,103,885
1,122,732
1,175,422
1,197,082
1,221,933
1,483,336
1,505,776
1,561,890
1,833,831
1,863,961
1,926,133
2,059,101
2,213,347
2,249,445
2,278,761
2,359,744
3,308,137
3,337,503
3,371,377
3,414,837
3,410,297
3,458,124
4,231,514
4,288,113
4,314,793
4,397,980
4,435,449
4,483,220
4,510,451
4,577,300
4,620,817
4,669,926
4,682,900
4,744,316
4,782,916
4,832,707
4,854,814
4,885,637
4,937,791
4,993,407
5,010,619
5,083,831
5,133,742
5,191,502
5,206,287
5,272,666
5,335,853
0
5,417,873
5,493,956
0
0

5,493,956

5,417,873

5,335,853

5,272,666

5,206,287

5,191,502

5,133,742

5,083,831

5,010,619

4,993,407

4,937,791

4,885,637

4,854,814

4,832,707

4,782,916

4,744,316

4,682,900

4,669,926

4,620,817

4,577,300

4,510,451

4,483,220

4,435,449

4,397,980

4,314,793

4,288,113

4,231,514

3,458,124

3,410,297

3,414,837

3,371,377

3,337,503

3,308,137

2,359,744

2,278,761

2,249,445

2,213,347

2,059,101

1,926,133

1,863,961

1,833,831

1,561,890

1,505,776

1,483,336

1,221,933

1,197,082

1,175,422

1,122,732

1,103,885

1,090,188

948,394

931,361

Treasury Stock

Other Stockholders Equity

50,700
49,700
146,300
145,863
149,097
151,039
156,696
158,545
161,172
205,659
209,312
0
321,863
337,929
340,476
319,038
406,059
411,605
412,355
414,110
414,929
420,577
420,758
421,141
421,214
422,256
482,658
485,570
618,806
623,048
703,283
709,359
765,540
772,294
784,317
794,917
814,458
828,434
841,657
852,065
861,519
871,669
886,251
898,235
916,666
929,046
946,218
1,088,223
1,102,152
1,118,829
1,171,487
1,193,147
1,218,395
1,476,732
1,499,173
1,555,287
1,828,116
1,856,468
1,918,682
2,051,680
2,206,616
2,239,299
2,269,078
2,350,049
3,298,746
3,323,595
3,357,480
3,401,221
3,396,737
3,443,155
4,216,545
4,273,792
4,300,690
4,383,691
4,420,976
4,468,996
4,496,434
4,563,910
4,607,402
4,656,625
4,669,988
4,734,105
4,772,955
4,822,746
4,844,982
4,874,959
4,927,035
4,983,568
5,001,061
5,073,624
5,123,517
5,181,813
5,196,898
5,263,376
5,326,528
5,396,036
5,407,924
5,483,563
5,532,381
5,601,702

5,601,702

5,532,381

5,483,563

5,407,924

5,396,036

5,326,528

5,263,376

5,196,898

5,181,813

5,123,517

5,073,624

5,001,061

4,983,568

4,927,035

4,874,959

4,844,982

4,822,746

4,772,955

4,734,105

4,669,988

4,656,625

4,607,402

4,563,910

4,496,434

4,468,996

4,420,976

4,383,691

4,300,690

4,273,792

4,216,545

3,443,155

3,396,737

3,401,221

3,357,480

3,323,595

3,298,746

2,350,049

2,269,078

2,239,299

2,206,616

2,051,680

1,918,682

1,856,468

1,828,116

1,555,287

1,499,173

1,476,732

1,218,395

1,193,147

1,171,487

1,118,829

1,102,152

1,088,223

946,218

929,046

916,666

898,235

886,251

871,669

861,519

852,065

841,657

828,434

814,458

794,917

784,317

772,294

765,540

709,359

703,283

623,048

618,806

485,570

482,658

422,256

421,214

421,141

420,758

420,577

414,929

414,110

412,355

411,605

406,059

319,038

340,476

337,929

321,863

209,312

205,659

161,172

158,545

156,696

151,039

149,097

145,863

146,300

49,700

50,700

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Accounts Payable	315,509	231,238	193,003	191,429	570,621	437,290	401,921	370,505	392,511	235,739	95,302	147,068	12,239	4,956	7,567	58,851	1,169	2,285	484	946	10,098	3,930	4,284	4,747	3,095	1,400
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-38,648	-3,867	14,432	-16,139	20,164	5,271	-22,961	12,816	21,033	27,466	5,018	-202	4,887	188	933	1,106	139	-25	-16	-363	5,057	5,031	2,385	-3,470	-5,101	-300
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	8,779	10,375	10,464	11,754	10,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	189	186	184	182	180	178	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	5,191,502	4,993,407	4,832,707	4,669,926	4,483,220	4,288,113	3,414,837	2,359,744	2,059,101	1,561,890	1,197,082	1,090,188	0	0	0	0	0	0	0	0	0	0	0	0
Cash	755,127	724,531	587,276	649,158	437,446	493,982	598,028	408,330	397,040	875,486	568,781	180,527	46,272	88,079	167,171	222,900	228,343	89,162	38,092	13,081	121,406	33,638	12,528	16,530	23,413	9,400
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	1,073,810	1,291,537	1,013,875	1,065,386	753,807	1,084,308	1,395,968	789,677	592,619	945,192	784,723	450,738	195,092	274,112	300,677	559,792	585,594	288,847	47,792	48,815	206,357	73,978	131,097	40,201	62,986	9,400
Common Stock	189	186	184	182	180	178	176	173	162	149	144	126	115	111	101	100	97	92	75	65	64	54	52	37	35	0
Common Stock Shares Outstanding	191,595	188,963	182,852	191,678	179,039	177,268	174,427	166,219	160,025	146,349	137,755	120,271	112,122	125,674	100,271	103,572	95,878	84,582	68,830	64,354	62,125	53,279	41,083	35,859	29,944	22,488
Common Stock Total Equity	0	0	184	182	180	178	176	173	162	149	144	126	115	111	101	100	97	92	75	65	64	54	52	37	35	0
Current Deferred Revenue	4,620	711	6,956	152	13,037	0	0	0	0	0	0	-77,847	0	212	86	307	5,327	7,092	8,096	24,400	0	0	2,198	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	460,952	399,095	446,786	220,191	166,296	150,391	225,501	222,649	236,017	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	33,296	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	196,199	196,199	196,199	196,199	197,039	197,039	197,039	197,039	197,039	54,258	54,258	51,543	51,543	53,364	23,722	21,262	21,262	21,262	21,262	45,053	0	0	0	0	0	0
Intangible Assets	294,701	338,569	388,652	417,271	456,580	491,808	517,510	553,780	683,996	156,578	163,147	162,980	180,277	103,648	40,977	7,626	9,596	11,655	36,558	61,504	0	0	0	9,862	11,462	11,700
Inventory	1,107,183	894,083	776,669	698,548	680,275	530,871	475,775	355,126	271,683	199,452	162,605	128,695	130,118	109,698	78,662	73,162	32,445	25,075	10,898	2,316	0	0	0	436	676	100
Liabilities And Stockholders Equity	6,841,603	6,375,074	6,003,325	5,848,020	4,690,039	4,427,128	4,633,125	4,023,690	3,729,368	2,490,453	2,249,217	1,601,643	1,303,681	1,262,623	917,163	906,695	815,279	463,436	195,303	232,966	256,340	110,616	171,811	76,933	103,549	31,500
Long Term Debt	593,095	1,083,019	1,079,077	1,075,145	486,238	830,417	813,521	660,761	662,286	657,976	655,566	324,859	348,329	377,521	497,168	497,353	563,928	292,488	212,922	228,038	125,672	3,383	3,961	56	0	0
Long Term Debt Total	0	0	1,079,077	1,075,145	486,238	830,417	813,521	660,761	662,286	657,976	655,566	324,859	348,329	377,521	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	611,135	333,835	507,793	285,473	411,978	235,864	385,785	572,711	443,708	98,895	268,516	117,073	94,944	129,253	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	378,748	358,488	491,801	425,987	410,674	336,435	576,442	274,909	265,246	-217,510	86,785	167,697	302,057	289,442	329,912	-152,159	275,341	141,565	186,167	257,762	3,594	-25,538	-6,976	-16,447	-23,302	-9,300
Net Invested Capital	6,038,521	5,686,175	5,349,817	5,181,147	3,970,501	3,798,357	3,983,133	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	633,704	461,316	373,399	448,351	377,404	342,633	261,365	215,280	164,959	144,472	117,822	109,066	104,839	86,576	73,540	54,298	16,976	14,670	5,860	4,047	0	0	3,096	2,934	2,466	700
Net Tangible Assets	0	4,068,388	3,685,889	3,492,532	2,468,762	2,279,093	2,094,114	2,015,456	1,519,812	1,317,058	1,123,636	801,240	541,228	560,245	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	1,779,064	2,162,573	1,734,563	1,849,671	1,009,640	1,532,974	1,390,626	982,481	644,182	1,189,890	954,147	573,029	375,677	420,416	389,573	607,615	582,754	288,179	28,574	15,223	212,454	74,225	128,481	37,658	61,335	10,800
Non Current Assets Total	3,885,515	3,623,617	3,728,940	3,505,801	2,747,896	2,370,913	2,425,981	2,601,899	2,639,729	1,064,824	1,111,799	858,181	833,879	758,363	449,436	168,999	170,982	129,212	126,362	147,689	31,071	29,544	35,028	32,392	37,127	18,700
Non Current Liabilities Other	119,935	100,015	113,686	174,325	148,917	105,530	194,423	157,344	77,251	68,844	69,339	57,292	88,179	84,001	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	713,030	1,183,034	1,192,763	1,249,470	635,155	935,947	1,007,944	818,105	883,064	726,820	724,905	415,447	436,508	461,522	516,824	499,939	566,010	299,589	232,398	230,890	125,672	5,226	3,961	56	85	100
Non Currrent Assets Other	121,216	176,236	151,760	142,237	122,009	36,568	29,852	32,815	408,644	65,281	143,171	16,611	15,495	14,215	15,306	12,584	63,306	40,829	52,483	43,684	5,917	1,338	2,468	1,815	572	800
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	1,604,192	1,600,835	1,574,387	611,997	496,578	428,947	475,537	628,835	200,766	293,562	242,112	238,144	250,232	15,306	12,584	18,425	9,372	20,490	20,555	5,917	1,338	1,323	10,195	0	0
Other Current Assets	141,391	104,521	110,442	129,934	130,657	98,403	74,036	61,708	60,378	105,310	41,707	25,509	39,753	33,874	14,848	50,444	9,282	5,632	4,391	4,801	18,912	7,094	2,590	970	294	2,600
Other Current Liab	354,239	346,560	329,399	289,213	-13,037	85,951	53,648	46,327	52,946	98,991	87,969	77,847	81,886	3,056	78,068	182	48,738	29,881	20,450	1,903	2,717	2,917	229	2,109	1,966	600
Other Liab	0	73,502	113,686	174,325	98,117	105,530	194,423	157,344	220,778	68,844	69,339	57,292	53,052	47,484	17,196	2,586	2,082	7,101	19,476	2,852	0	1,843	0	0	0	0
Other Stockholder Equity	5,611,562	5,396,036	5,181,813	4,983,568	4,822,746	4,656,625	4,468,996	4,273,792	3,401,221	2,350,049	2,051,680	1,555,287	1,193,147	1,088,223	898,235	852,065	794,917	709,359	485,570	421,141	414,110	319,038	321,863	158,545	145,863	44,800
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	1,933,222	1,875,511	1,756,035	1,032,471	1,010,868	948,682	896,700	798,768	704,207	523,516	319,316	284,473	268,971	221,866	199,141	124,979	76,818	55,466	37,321	42,501	25,154	28,206	32,560	20,715	25,093	6,200
Property Plant And Equipment Net	1,112,207	1,073,366	1,035,461	1,032,471	1,010,868	948,682	896,700	798,768	704,207	523,516	319,316	284,473	268,971	221,866	199,141	124,979	76,818	55,466	37,321	42,501	25,154	28,206	32,560	20,715	25,093	6,200
Property Plant Equipment	0	1,114,322	1,035,461	1,032,471	1,010,868	948,682	896,700	798,768	704,207	523,516	319,316	284,473	268,971	221,866	199,141	124,979	76,818	55,466	37,321	42,501	25,154	28,206	32,560	20,715	0	0
Retained Earnings	-621,554	-789,199	-925,689	-861,609	-1,720,709	-1,694,134	-1,637,548	-1,520,506	-1,021,569	-849,770	-715,801	-539,448	-425,101	-371,265	-577,084	-576,596	-607,427	-591,624	-563,091	-488,821	-301,378	-225,580	-148,119	-80,513	-43,149	-15,100
Retained Earnings Total Equity	0	0	-925,689	-861,609	-1,720,709	-1,694,134	-1,637,548	-1,520,506	-1,021,569	-849,770	-715,801	-539,448	-425,101	-371,265	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	493,877	0	0	0	361,882	0	360,949	22,478	662,286	642,902	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	1,133,875	1,083,019	1,079,077	1,075,145	848,120	830,417	1,174,470	683,239	662,286	657,976	655,566	348,224	348,329	377,521	497,083	70,741	503,684	230,727	224,259	270,843	125,000	8,100	5,552	83	111	100
Short Term Debt	502,656	10,375	10,464	11,754	361,882	0	360,949	22,478	662,286	642,902	0	23,365	0	75,620	0	70,741	6,309	6,787	11,337	42,805	0	0	1,591	27	26	0
Short Term Investments	318,683	567,006	426,599	416,228	316,361	590,326	797,940	381,347	195,579	69,706	215,942	270,211	148,820	186,033	133,506	336,892	357,251	199,685	9,700	35,734	84,951	40,340	118,569	23,671	39,573	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	6,841,603	6,375,074	6,003,325	5,848,020	4,690,039	4,427,128	4,633,125	4,023,690	3,729,368	2,490,453	2,249,217	1,601,643	1,303,681	1,262,623	917,163	906,695	815,279	463,436	195,303	232,966	256,340	110,616	171,811	76,933	103,549	31,500
Total Current Assets	2,956,088	2,751,457	2,274,385	2,342,219	1,942,143	2,056,215	2,207,144	1,421,791	1,089,639	1,425,629	1,137,418	743,462	469,802	504,260	467,727	737,696	644,297	334,224	68,941	85,277	225,269	81,072	136,783	44,541	66,422	12,800
Total Current Liabilities	1,177,024	588,884	539,822	492,548	932,503	523,241	816,518	439,310	445,457	235,739	183,271	170,433	94,125	83,844	78,154	130,081	61,543	46,045	40,367	70,054	12,815	6,847	8,302	6,883	5,087	2,000
Total Liab	1,890,054	1,771,918	1,732,585	1,742,018	1,567,658	1,459,188	1,824,462	1,257,415	1,328,521	962,559	908,176	585,880	530,633	545,366	594,978	630,020	627,553	345,634	272,765	300,944	138,487	12,073	12,263	6,939	5,172	2,100
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	4,951,549	4,603,156	4,270,740	4,106,002	3,122,381	2,967,940	2,808,663	2,766,275	2,400,847	1,527,894	1,341,041	1,015,763	773,048	717,257	322,185	276,675	187,726	117,802	-77,462	-67,978	117,853	98,543	159,548	69,994	98,377	29,400
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31
Accounts Payable	683,147	301,369	277,944	264,778	231,238	207,165	199,251	187,810	193,003	203,321	411,132	399,225	191,429	218,021	443,202	454,506	570,621	483,745	429,502	412,830	437,290	378,226	358,732	346,538	401,921	364,920	158,229	135,604	370,505	306,129	292,342	290,562	392,511	296,200	256,330	230,212	235,739	206,550	166,720	156,038	95,302	167,633	142,241	144,008	147,068	11,459	12,501	12,439	12,239	7,107	7,252	5,274	4,956	7,184	9,708	3,276	7,567	2,076	31,012	5,178	58,851	2,029	2,847	2,326	1,169	1,313	754	748	2,285	1,498	231	440	484	539	2,324	2,470	946	466	840	2,299	10,098	13,399	12,123	9,532	3,930	763	2,014	4,284	4,284	3,923	3,049	1,616	4,747	1,792	990	1,367	3,095	5,000	6,000	800
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-28,788	6,257	-18,617	-10,722	-3,867	30,749	18,472	-877	14,432	10,239	-939	5,004	-16,139	10,385	30,050	34,127	20,164	37,003	17,439	19,794	5,271	-2,160	-1,129	-28,545	-22,961	-21,434	-14,658	5,020	12,816	2,158	4,528	47	21,033	25,184	32,461	43,819	27,466	19,189	9,941	7,275	5,018	11,473	2,441	1,155	-202	2,333	4,650	2,512	4,887	1,304	-5,923	-5,787	188	-1,581	10,224	4,405	933	-704	101	2,069	1,106	-2,754	-575	351	139	128	-7	-5	-25	-24	-49	-15	-16	-16	-144	-235	-363	-260	-530	5,102	5,057	5,195	5,128	5,043	5,031	3,996	3,046	2,385	-14,248	2,217	2,033	-3,285	-3,470	-3,422	-4,510	-4,832	-5,101	-5,400	-5,800	-6,000
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	8,779	9,324	8,294	9,251	10,375	9,226	10,611	10,829	10,464	9,659	11,024	11,227	11,754	10,930	11,387	10,401	10,700	10,225	10,165	9,210	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	189	188	188	188	186	186	186	185	184	184	183	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	5,493,956	5,417,873	0	5,335,853	5,272,666	5,206,287	5,191,502	5,133,742	5,083,831	5,010,619	4,993,407	4,937,791	4,885,637	4,854,814	4,832,707	4,782,916	4,744,316	4,682,900	4,669,926	4,620,817	4,577,300	4,510,451	4,483,220	4,435,449	4,397,980	4,314,793	4,288,113	4,231,514	3,458,124	3,410,297	3,414,837	3,371,377	3,337,503	3,308,137	2,359,744	2,278,761	2,249,445	2,213,347	2,059,101	1,926,133	1,863,961	1,833,831	1,561,890	1,505,776	1,483,336	1,221,933	1,197,082	1,175,422	1,122,732	1,103,885	1,090,188	948,394	931,361	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	755,127,000	785,414	694,381	580,074	724,531	761,515	619,802	605,440	587,276	617,143	641,533	667,313	649,158	1,015,675	818,900	476,632	437,446	423,220	307,577	364,369	493,982	882,184	427,411	473,980	598,028	431,399	354,864	348,234	408,330	707,349	305,969	270,453	397,040	376,346	440,664	900,570	875,486	398,005	584,717	639,778	568,781	181,565	175,445	154,380	180,527	181,330	177,757	82,586	46,272	71,254	112,956	90,782	88,079	127,539	115,779	108,963	167,171	191,778	200,050	214,579	222,900	271,217	252,209	319,990	228,343	291,825	205,010	98,331	89,162	191,782	285,990	341,689	38,092	56,213	17,111	11,246	13,081	34,981	48,247	96,199	121,406	187,978	221,772	125,835	33,638	32,405	19,363	12,528	12,528	7,230	18,967	19,722	16,530	16,098	10,609	40,675	23,413	32,600	17,200	3,600
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	1,073,810	1,125,845	1,170,958	1,152,091	1,291,537	1,273,768	1,109,747	1,056,238	1,013,875	1,079,476	1,123,397	1,087,491	1,065,386	1,505,673	1,380,372	858,396	753,807	720,792	731,103	894,854	1,084,308	1,443,376	1,363,073	1,382,795	1,395,968	1,257,099	727,776	678,055	789,677	1,034,848	503,287	456,853	592,619	618,330	681,553	1,008,689	945,192	666,373	836,618	887,481	784,723	379,651	400,561	401,882	450,738	426,455	402,586	232,979	195,092	224,374	258,920	252,581	274,112	351,967	337,673	323,642	300,677	363,344	346,391	551,869	559,792	562,969	575,657	574,762	585,594	586,686	587,710	273,307	288,847	293,900	305,900	347,689	47,792	65,913	26,685	29,759	48,815	86,551	128,796	191,198	206,357	241,889	266,360	148,578	73,978	86,468	100,558	131,097	0	43,905	59,885	29,766	40,201	47,505	49,412	55,674	62,986	72,200	17,500	3,900
Common Stock	189	188	188	188	186	186	186	185	184	184	183	183	182	181	181	181	180	180	179	179	178	178	178	177	176	176	175	173	173	173	164	163	162	162	161	161	149	148	147	146	144	142	140	139	126	124	123	116	115	114	112	111	111	103	102	102	101	101	100	100	100	100	99	98	97	97	96	96	92	91	85	85	75	74	65	65	65	64	64	64	64	64	64	63	54	54	53	52	52	42	42	37	37	37	35	35	35	0	0	0
Common Stock Shares Outstanding	191,838	191,173	194,998	194,363	186,028	185,597	187,448	194,886	183,554	183,214	185,427	184,365	184,476	197,674	180,729	187,163	182,412	185,924	179,048	178,271	178,143	177,481	176,873	176,150	175,705	175,103	174,374	172,710	172,240	167,714	162,587	161,548	174,288	161,134	160,406	157,612	148,202	159,304	146,351	144,157	144,157	140,796	139,596	127,969	124,575	123,434	117,912	115,070	115,070	112,290	111,114	110,743	110,743	131,278	101,834	103,720	103,720	101,906	101,217	99,933	99,933	103,403	104,120	103,869	103,869	96,199	95,796	94,557	94,557	86,269	85,341	74,963	74,963	71,996	64,605	64,511	64,511	64,384	64,339	64,225	64,225	63,815	63,494	56,964	56,964	53,446	53,407	52,535	42,136	42,136	39,587	37,052	37,052	36,064	35,397	35,015	35,015	31,667	26,154	26,176
Common Stock Total Equity	0	0	188	188	0	186	186	185	184	184	183	183	182	181	181	181	180	180	179	179	178	178	178	177	176	176	175	173	173	173	164	163	162	162	161	161	149	148	147	146	144	142	140	139	126	124	123	116	115	114	112	111	111	103	102	102	101	101	100	100	100	100	99	98	97	97	96	96	92	91	85	85	75	74	65	65	65	64	64	64	64	64	64	63	54	54	53	53	52	42	42	37	37	37	35	35	35	0	0	0
Current Deferred Revenue	-1,742,469	-301,369	-286,238	0	711	415	305	306	6,956	253,731	-11,024	-11,227	152	3,240	5,350	7,889	13,037	-10,225	-10,165	-9,210	0	0	0	0	0	17,430	0	136,843	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-77,847	1,084	1,442	4,293	0	0	0	0	212	0	0	158	86	149	929	120	307	1,443	3,236	4,879	5,327	6,639	7,154	7,154	7,092	7,242	8,226	9,893	8,096	9,592	9,842	20,883	24,400	18,659	12,381	0	-118,396	0	0	0	0	0	0	2,198	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	475,554	467,333	460,952	429,194	425,380	407,009	399,095	484,759	470,961	458,387	446,786	288,006	266,182	243,212	220,191	146,245	172,545	163,411	166,296	150,991	147,143	144,124	150,391	238,703	235,400	226,757	225,501	229,771	220,593	221,239	222,649	229,172	228,400	231,947	236,017	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	143,527	143,527	193,202	193,202	193,202	0	0	0	0	0	37,190	37,182	37,521	33,296	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	196,199	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	197,039	202,392	202,392	202,392	54,258	54,258	54,258	54,258	54,258	54,258	54,975	54,975	51,543	51,543	51,543	51,543	51,543	51,543	53,055	53,055	53,364	53,364	40,360	40,360	23,722	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	21,262	45,053	32,250	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	294,701	302,476	310,343	325,989	338,569	354,024	369,368	374,251	388,652	388,487	394,298	405,903	417,271	427,172	433,381	443,717	456,580	462,849	476,632	485,981	491,808	494,687	502,295	509,902	517,510	530,957	538,565	546,172	553,780	561,387	568,966	1,177,232	683,996	920,943	923,861	926,896	156,578	159,949	163,045	165,397	163,147	165,791	168,434	172,016	162,980	165,624	168,267	170,914	180,277	100,780	101,736	102,692	103,648	104,604	77,985	77,416	40,977	4,194	4,391	6,316	7,626	6,068	7,244	8,420	9,596	8,377	9,470	10,563	11,655	12,748	13,841	14,934	36,558	36,854	37,140	37,427	61,504	131,373	133,090	0	0	0	0	0	0	0	0	0	0	8,314	8,868	9,333	9,862	10,345	10,856	11,159	11,462	11,600	11,900	11,400
Inventory	1,107,183	1,032,159	975,546	918,921	894,083	839,460	802,315	786,356	776,669	749,406	710,975	713,929	698,548	700,847	743,852	705,652	680,275	609,049	578,736	534,696	530,871	508,482	473,356	468,161	475,775	457,393	429,831	384,143	355,126	347,420	326,556	296,979	271,683	262,100	237,532	222,833	199,452	204,444	193,498	176,893	162,605	148,684	142,296	135,822	128,695	120,825	120,125	124,064	130,118	115,628	112,299	110,067	109,698	91,741	83,778	79,761	78,662	75,441	72,836	76,423	73,162	68,094	61,802	54,736	32,445	31,551	30,714	27,438	25,075	25,762	24,247	18,137	10,898	7,720	3,386	2,439	2,316	3,090	2,074	0	0	0	0	0	0	0	0	0	0	525	480	439	436	446	495	647	676	900	800	100
Liabilities And Stockholders Equity	6,841,603	6,758,163	6,563,172	6,433,695	6,375,074	6,264,040	6,145,841	6,062,707	6,003,325	5,977,475	5,898,496	5,805,053	5,848,020	6,158,090	5,302,110	4,722,841	4,690,039	4,558,128	4,393,384	4,435,398	4,427,128	4,695,254	4,624,679	4,596,717	4,633,125	4,580,697	4,019,965	3,938,607	4,023,690	3,842,238	3,087,304	3,666,993	3,729,368	3,624,853	3,648,689	3,658,686	2,490,453	2,440,433	2,345,685	2,340,728	2,249,217	1,620,530	1,601,520	1,598,293	1,601,643	1,567,376	1,532,527	1,297,085	1,303,681	1,295,076	1,280,392	1,264,146	1,262,623	1,244,533	985,516	966,205	917,163	869,357	844,437	900,283	906,695	859,038	854,555	827,702	815,279	791,056	781,639	449,764	463,436	467,072	468,714	488,229	195,303	208,842	167,247	180,933	232,966	312,230	347,416	239,296	256,340	284,446	306,385	183,117	110,616	127,469	141,973	171,811	171,811	90,402	98,321	65,443	76,933	83,324	86,090	94,490	103,549	112,500	51,400	26,800
Long Term Debt	593,095	592,586	1,084,994	1,084,006	1,083,019	1,082,033	1,081,047	1,080,061	1,079,077	1,078,093	1,077,110	1,076,127	1,075,145	1,074,164	1,073,202	486,713	486,238	843,616	839,165	834,766	830,417	826,119	821,871	817,672	813,521	1,166,036	676,205	668,437	660,761	653,178	645,685	668,009	662,286	667,793	661,492	655,491	657,976	656,884	650,872	661,419	655,566	78,310	109,822	109,849	324,859	324,861	324,865	324,872	348,329	348,339	377,520	377,521	377,521	497,083	497,083	497,125	497,168	497,216	497,262	497,305	497,353	497,240	563,188	563,456	563,928	564,321	564,707	240,445	292,488	293,084	367,311	367,836	212,922	214,447	215,965	217,424	228,038	222,062	222,252	125,000	125,672	125,000	125,000	2,680	3,383	2,912	3,463	3,503	3,961	146	198	47	56	63	68	77	0	0	0	0
Long Term Debt Total	0	0	1,084,994	1,084,006	0	1,082,033	1,081,047	1,080,061	1,079,077	1,078,093	1,077,110	1,076,127	1,075,145	1,074,164	1,073,202	486,713	486,238	853,160	839,165	834,766	830,417	826,119	821,871	817,672	813,521	1,166,036	676,205	668,437	660,761	653,178	645,685	668,009	662,286	667,793	661,492	655,491	657,976	656,884	650,872	661,419	655,566	78,310	109,822	109,849	324,859	324,861	324,865	324,872	348,329	348,339	377,520	377,521	377,521	497,083	497,083	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	611,135	548,002	385,777	340,635	333,835	372,302	412,503	462,827	507,793	466,618	350,237	321,127	285,473	265,122	323,058	290,796	411,978	431,804	374,965	320,000	235,864	204,883	279,988	313,599	385,785	416,304	482,036	533,628	572,711	362,956	201,620	314,404	443,708	514,381	509,627	224,810	98,895	449,143	244,588	251,928	268,516	148,625	124,906	124,498	117,073	107,589	123,155	55,833	94,944	146,808	154,327	142,511	129,253	90,116	118,085	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	-754,040,028	300,570	390,613	503,932	358,488	320,518	461,245	485,450	491,801	460,950	435,577	408,814	425,987	432,779	624,402	376,045	410,674	420,396	531,588	470,397	336,435	318,165	764,212	709,018	576,442	734,637	321,341	342,698	274,909	-31,711	364,136	397,556	265,246	291,447	220,828	-245,079	-217,510	258,879	66,155	21,641	86,785	-103,255	-65,623	-44,531	167,697	166,971	170,548	265,741	302,057	277,085	264,564	286,739	289,442	369,544	381,304	388,120	329,912	305,305	297,033	352,821	344,924	226,023	250,852	183,375	275,341	279,045	366,482	148,900	141,565	108,089	88,026	53,195	186,167	169,930	210,999	158,413	257,762	235,828	138,759	28,801	3,594	-62,978	-96,772	-121,335	-28,438	-29,493	-15,863	-6,976	-6,976	-6,989	-18,671	-19,646	-16,447	-16,007	-10,512	-40,572	-23,302	-32,500	8,900	-3,500
Net Invested Capital	6,038,521	5,982,881	5,867,821	5,743,049	5,686,175	5,650,547	5,585,854	5,471,376	5,349,817	5,344,242	5,318,681	5,238,137	5,181,147	5,502,347	4,679,981	4,092,639	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	633,704	572,498	610,222	597,913	461,316	419,622	466,507	430,147	373,399	374,937	424,419	396,097	448,351	411,712	381,215	396,384	377,404	402,970	377,150	393,429	342,633	384,343	363,566	318,394	261,365	251,891	238,338	230,250	215,280	215,894	214,158	180,751	164,959	148,949	186,083	175,738	144,472	121,395	122,282	110,462	117,822	124,745	115,063	120,345	109,066	117,290	100,750	105,828	110,932	107,057	106,606	106,198	93,884	78,734	77,682	82,606	73,540	68,378	81,346	61,355	54,298	51,135	52,156	47,253	16,976	15,968	15,900	14,525	14,670	13,000	10,946	7,493	5,860	5,328	2,871	1,831	4,047	119	4,612	0	0	0	0	0	0	2,332	2,135	3,096	3,096	4,851	2,231	754	2,934	2,960	3,018	5,006	2,466	400	1,500	900
Net Tangible Assets	0	4,398,222	4,276,285	4,136,855	4,068,388	4,018,291	3,939,240	3,820,865	3,685,889	3,681,463	3,651,074	3,559,908	3,492,532	3,430,522	2,607,099	2,600,046	2,468,762	2,414,517	2,287,283	2,253,607	2,279,093	2,223,219	2,185,770	2,100,062	2,094,114	2,085,566	2,059,975	2,025,876	2,015,456	1,887,382	1,151,571	915,965	1,519,812	1,169,305	1,230,704	1,296,167	1,317,058	1,294,235	1,244,666	1,240,466	1,123,636	1,056,437	1,034,849	1,023,161	801,240	798,027	780,616	549,493	541,228	622,216	577,514	565,093	560,245	427,696	244,617	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	1,779,064	1,792,085	2,352,886	2,243,874	2,162,573	2,161,681	2,052,871	1,903,606	1,734,563	1,796,672	1,914,493	1,858,731	1,849,671	1,884,286	1,834,264	1,295,779	1,009,640	1,365,614	1,367,340	1,415,869	1,532,974	1,569,193	1,475,117	1,467,639	1,390,626	1,632,500	1,084,517	1,012,582	982,481	1,289,236	741,366	604,779	644,182	785,098	866,225	1,217,222	1,189,890	871,269	1,053,507	1,090,372	954,147	545,846	578,679	579,016	573,029	584,457	561,537	393,576	375,677	403,770	432,076	427,844	420,416	462,092	437,978	421,732	389,573	456,197	446,948	587,261	607,615	576,278	638,391	630,417	582,754	592,172	596,389	281,816	288,179	296,137	306,803	321,872	28,574	37,964	-4,366	2,904	15,223	64,972	100,317	193,664	212,454	237,963	259,801	142,076	74,225	83,023	97,824	128,481	128,481	44,552	58,463	32,224	37,658	47,805	50,706	56,870	61,335	70,800	13,200	3,900
Non Current Assets Total	3,885,515	3,802,855	3,613,055	3,591,590	3,623,617	3,581,339	3,628,243	3,668,683	3,728,940	3,665,905	3,540,659	3,516,287	3,505,801	3,419,111	2,654,544	2,606,592	2,747,896	2,698,769	2,586,616	2,518,543	2,370,913	2,287,401	2,344,612	2,355,607	2,425,981	2,530,668	2,561,145	2,585,819	2,601,899	2,175,667	1,981,358	2,674,203	2,639,729	2,449,264	2,434,760	2,135,958	1,064,824	1,362,614	1,125,458	1,094,318	1,111,799	907,051	880,600	875,269	858,181	847,990	850,993	783,695	833,879	808,052	766,281	760,316	758,363	690,344	463,608	465,774	449,436	349,090	337,456	186,708	168,999	162,025	152,741	143,974	170,982	149,822	140,707	129,119	129,212	127,706	123,907	109,470	126,362	126,654	127,911	127,334	147,689	171,543	165,829	30,471	31,071	30,240	31,333	28,322	29,544	36,099	36,418	35,028	35,028	39,760	34,735	29,582	32,392	31,910	32,558	32,938	37,127	36,100	30,300	21,300
Non Current Liabilities Other	119,935	105,457	98,120	92,415	100,015	92,473	95,260	100,913	113,686	118,335	105,711	136,881	174,325	175,340	178,927	175,696	148,917	97,432	153,837	163,019	105,530	115,530	112,754	198,571	194,423	183,570	173,878	160,877	157,344	165,917	159,463	177,210	77,251	80,727	89,334	79,032	68,844	68,557	66,124	63,150	69,339	60,911	54,017	56,763	57,292	92,392	87,239	80,449	88,179	88,944	88,532	89,799	84,001	69,689	41,541	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	713,030	698,043	1,183,114	1,176,421	1,183,034	1,174,506	1,176,307	1,180,974	1,192,763	1,196,428	1,213,581	1,213,008	1,249,470	1,249,504	1,252,129	662,409	635,155	989,978	993,002	997,785	935,947	941,649	934,625	1,016,243	1,007,944	1,349,606	850,083	829,314	818,105	819,095	805,148	988,746	883,064	941,722	944,028	927,725	726,820	725,441	716,996	724,569	724,905	176,411	201,021	204,133	415,447	417,253	412,104	405,321	436,508	437,283	466,052	467,320	461,522	566,772	538,624	542,266	516,824	501,434	500,970	500,029	499,939	500,402	565,105	565,225	566,010	567,449	569,494	246,221	299,589	301,726	381,823	385,337	232,398	229,997	233,987	220,473	230,890	222,352	222,956	125,363	125,672	126,240	128,697	4,496	5,226	2,912	3,463	3,961	3,961	146	198	47	56	63	68	77	85	100	26,100	100
Non Currrent Assets Other	171,538	165,069	144,168	150,057	176,236	151,788	151,797	149,186	151,760	144,705	141,663	141,198	142,237	119,009	135,852	125,918	122,009	112,646	99,456	96,300	36,568	37,565	39,430	32,666	29,852	22,985	21,447	26,580	32,815	36,443	23,057	25,400	408,644	60,790	58,284	80,332	65,281	61,532	46,562	41,545	143,171	14,010	14,883	15,158	16,611	19,739	20,061	19,849	15,495	13,559	12,267	12,227	14,215	12,413	14,558	14,112	15,306	12,578	12,689	12,500	12,584	23,979	19,036	18,560	63,306	53,934	51,195	40,807	40,829	41,227	37,189	37,023	52,483	52,001	51,215	48,728	43,684	4,550	5,739	6,024	5,917	6,247	6,433	1,984	1,338	5,105	3,714	2,468	2,468	3,450	2,946	266	1,815	1,534	1,315	1,036	572	1,600	1,400	1,300
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	1,677,822	1,642,158	1,660,625	1,604,192	1,606,993	1,600,709	1,579,362	1,600,835	1,589,814	1,573,346	1,570,584	1,574,387	1,449,774	628,166	665,908	611,997	576,147	515,215	510,203	496,578	463,825	463,194	1,460,215	1,529,281	1,652,044	1,710,048	1,761,806	1,803,131	1,445,831	1,256,864	1,957,287	1,935,522	1,844,751	1,866,709	1,597,841	541,308	875,873	655,596	657,252	792,483	621,387	598,598	593,404	573,708	574,266	583,619	519,378	564,908	541,862	549,785	542,432	536,497	476,589	250,988	261,825	250,295	166,991	177,667	44,456	44,020	51,309	47,542	48,242	94,164	83,573	81,927	72,632	73,746	75,237	72,292	73,219	89,041	88,855	88,355	86,155	105,188	135,923	138,829	6,024	5,917	6,247	6,433	1,984	1,338	5,105	3,714	821	2,468	11,764	11,814	9,599	11,677	11,879	12,171	12,195	0	0	0	0
Other Current Assets	141,391	224,806	193,391	173,180	104,521	149,851	139,029	121,283	110,442	107,751	99,046	91,249	129,934	120,747	142,127	155,817	130,657	126,548	119,779	93,876	98,403	71,652	80,072	71,760	74,036	83,646	62,875	60,340	61,708	68,409	61,945	58,207	60,378	115,330	77,558	84,265	105,310	56,458	37,268	41,013	41,707	28,161	33,526	35,501	25,509	54,816	58,073	50,519	4,994	39,965	36,286	34,984	235	31,747	22,775	14,422	14,848	13,104	239	23,928	50,444	14,815	12,199	6,977	9,282	7,029	6,608	5,375	5,632	6,704	3,714	5,440	4,391	3,227	6,275	6,640	4,801	25,729	20,981	17,627	18,912	12,317	8,692	6,217	7,094	2,570	2,862	2,590	2,590	1,361	990	3,386	970	503	607	225	294	2,900	1,300	600
Other Current Liab	683,147	669,825	597,231	324,202	346,560	304,214	254,560	291,473	329,399	48,187	32,212	30,810	289,213	259,142	-5,350	-7,889	-13,037	10,000	9,926	88,156	85,951	86,204	76,466	61,607	53,648	52,609	216,074	45,264	46,327	48,746	47,818	97,449	52,946	94,291	91,374	75,294	98,991	86,093	62,934	72,811	87,969	89,095	69,926	72,195	77,847	98,946	82,614	79,627	81,886	76,147	74,783	70,712	3,056	84,913	74,222	75,265	78,068	61,845	28,092	50,699	182	72,070	51,524	40,041	48,738	34,561	29,850	24,141	29,881	27,702	22,842	19,506	20,450	22,397	19,391	2,286	1,903	7,843	9,821	12,862	2,717	2,844	3,128	3,187	2,917	7,584	5,717	229	2,427	2,072	1,976	1,992	2,109	1,789	1,807	3,289	1,966	600	1,900	800
Other Liab	0	105,457	0	92,415	73,502	92,473	95,260	100,913	113,686	118,335	136,471	136,881	174,325	129,939	132,099	175,696	98,117	91,319	99,958	115,068	105,530	115,530	112,754	198,571	194,423	183,570	173,878	160,877	157,344	165,917	159,463	177,210	77,251	80,727	89,334	79,032	68,844	68,557	66,124	63,150	69,339	60,911	54,017	56,763	57,292	59,694	54,541	47,751	53,052	52,427	52,015	53,282	47,484	42,552	25,100	28,700	17,196	4,218	3,708	2,724	2,586	3,162	1,917	1,769	2,082	3,128	4,787	5,776	7,101	8,642	14,512	17,501	19,476	15,550	18,022	3,049	2,852	290	704	363	0	1,240	3,697	1,816	1,843	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Stockholder Equity	5,601,702	5,532,381	5,483,563	5,407,924	5,396,036	5,326,528	5,263,376	5,196,898	5,181,813	5,123,517	5,073,624	5,001,061	4,983,568	4,927,035	4,874,959	4,844,982	4,822,746	4,772,955	4,734,105	4,669,988	4,656,625	4,607,402	4,563,910	4,496,434	4,468,996	4,420,976	4,383,691	4,300,690	4,273,792	4,216,545	3,443,155	3,396,737	3,401,221	3,357,480	3,323,595	3,298,746	2,350,049	2,269,078	2,239,299	2,206,616	2,051,680	1,918,682	1,856,468	1,828,116	1,555,287	1,499,173	1,476,732	1,218,395	1,193,147	1,171,487	1,118,829	1,102,152	1,088,223	946,218	929,046	916,666	898,235	886,251	871,669	861,519	852,065	841,657	828,434	814,458	794,917	784,317	772,294	765,540	709,359	703,283	623,048	618,806	485,570	482,658	422,256	421,214	421,141	420,758	420,577	414,929	414,110	412,355	411,605	406,059	319,038	340,476	337,929	321,863	0	209,312	205,659	161,172	158,545	156,696	151,039	149,097	145,863	146,300	49,700	50,700
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	1,933,222	1,918,609	1,896,455	1,875,086	1,875,511	1,834,220	0	0	0	0	1,026,579	1,022,474	1,032,471	1,015,062	1,010,917	1,009,972	1,010,868	969,300	962,970	951,890	948,682	924,033	900,480	895,392	896,700	878,624	851,097	824,013	798,768	729,836	724,494	716,916	704,207	604,513	568,051	538,117	523,516	486,741	469,862	437,066	319,316	285,664	282,002	281,865	284,473	273,724	267,374	264,317	268,971	266,190	216,496	217,884	221,866	213,755	212,620	203,949	199,141	182,099	159,789	142,252	124,979	110,716	105,199	95,732	76,818	66,249	58,780	56,487	55,466	52,469	51,615	36,251	37,321	37,799	39,556	41,179	42,501	35,620	27,000	24,447	25,154	23,993	24,900	26,338	28,206	30,994	32,704	33,059	32,560	27,996	22,921	19,983	20,715	20,031	20,387	20,743	25,093	22,900	17,000	8,600
Property Plant And Equipment Net	1,066,133	1,067,156	1,067,278	1,068,142	1,073,366	1,051,821	1,049,464	1,039,544	1,035,461	1,024,787	1,026,579	1,022,474	1,032,471	1,015,062	1,010,917	1,009,972	1,010,868	969,300	962,970	951,890	948,682	924,033	900,480	895,392	896,700	878,624	851,097	824,013	798,768	729,836	724,494	716,916	704,207	604,513	568,051	538,117	523,516	486,741	469,862	437,066	319,316	285,664	282,002	281,865	284,473	273,724	267,374	264,317	268,971	266,190	216,496	217,884	221,866	213,755	212,620	203,949	199,141	182,099	159,789	142,252	124,979	110,716	105,199	95,732	76,818	66,249	58,780	56,487	55,466	52,469	51,615	36,251	37,321	37,799	39,556	41,179	42,501	35,620	27,000	24,447	25,154	23,993	24,900	26,338	28,206	30,994	32,704	32,560	0	27,996	22,921	19,983	20,715	20,031	20,387	20,743	25,093	22,900	17,000	8,600
Property Plant Equipment	0	1,067,156	1,067,278	1,068,142	1,114,322	1,051,821	1,049,464	1,039,544	1,035,461	1,024,787	1,026,579	1,022,474	1,032,471	1,015,062	1,010,917	1,009,972	1,010,868	1,030,930	962,970	951,890	948,682	924,033	900,480	895,392	896,700	878,624	851,097	824,013	798,768	729,836	724,494	716,916	704,207	604,513	568,051	538,117	523,516	486,741	469,862	437,066	319,316	285,664	282,002	281,865	284,473	273,724	267,374	264,317	268,971	266,190	216,496	217,884	221,866	213,755	212,620	203,949	199,141	182,099	159,789	142,252	124,979	110,716	105,199	95,732	76,818	66,249	58,780	56,487	55,466	52,469	51,615	36,251	37,321	37,799	39,556	41,179	42,501	35,620	27,000	24,447	25,154	23,993	24,900	26,338	28,206	30,994	32,704	33,059	32,560	27,996	22,921	19,983	20,715	20,031	20,387	20,743	0	0	0	0
Retained Earnings	-621,554	-641,929	-682,307	-738,347	-789,199	-788,949	-777,227	-804,891	-925,689	-867,791	-831,297	-844,238	-861,609	-883,708	-1,668,511	-1,639,328	-1,720,709	-1,735,733	-1,790,769	-1,753,334	-1,694,134	-1,690,475	-1,677,855	-1,661,063	-1,637,548	-1,586,156	-1,573,629	-1,536,796	-1,520,506	-1,573,068	-1,530,271	-1,106,711	-1,021,569	-1,090,186	-999,260	-917,271	-849,770	-779,973	-787,418	-753,916	-715,801	-653,811	-600,791	-579,258	-539,448	-486,436	-481,079	-449,073	-425,101	-398,366	-380,713	-375,636	-371,265	-359,076	-576,410	-575,933	-577,084	-581,795	-588,436	-589,748	-576,596	-601,102	-601,931	-605,741	-607,427	-609,997	-604,781	-600,917	-591,624	-581,233	-574,197	-572,871	-563,091	-548,095	-532,619	-511,279	-488,821	-406,399	-376,921	-321,323	-301,378	-275,651	-254,360	-245,263	-225,580	-206,250	-189,133	-148,119	-148,119	-113,197	-102,182	-90,213	-80,513	-70,119	-61,970	-54,884	-43,149	-34,100	-26,500	-19,600
Retained Earnings Total Equity	0	0	-682,307	-738,347	0	-788,949	-777,227	-804,891	-925,689	-867,791	-831,297	-844,238	-861,609	-883,708	-1,668,511	-1,639,328	-1,720,709	0	-1,790,769	-1,753,334	-1,694,134	-1,690,475	-1,677,855	-1,661,063	-1,637,548	-1,586,156	-1,573,629	-1,536,796	-1,520,506	-1,573,068	-1,530,271	-1,106,711	-1,021,569	-1,090,186	-999,260	-917,271	-849,770	-779,973	-787,418	-753,916	-715,801	-653,811	-600,791	-579,258	-539,448	-486,436	-481,079	-449,073	-425,101	-398,366	-380,713	-375,636	-371,265	-359,076	-576,410	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	493,877	493,398	0	0	0	0	0	0	0	0	0	0	0	374,290	370,100	365,964	361,882	0	0	6,347	0	374,230	369,752	365,326	360,949	1,166,036	676,205	67,759	22,478	71,206	72,238	0	662,286	0	0	0	642,902	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	1,086,972	1,085,984	1,084,994	1,084,006	1,083,019	1,082,033	1,081,047	1,090,890	1,079,077	1,078,093	1,077,110	1,076,127	1,075,145	1,448,454	1,443,302	852,677	848,120	843,616	839,165	834,766	830,417	1,200,349	1,191,623	1,182,998	1,174,470	1,166,036	676,205	690,932	683,239	675,638	670,105	668,009	662,286	667,793	661,492	655,491	657,976	656,884	650,872	661,419	655,566	78,310	109,822	109,849	348,224	348,301	348,305	348,327	348,329	348,339	377,520	377,521	377,521	497,083	497,083	497,083	497,083	497,083	497,083	567,400	567,824	497,240	503,061	503,365	503,684	570,870	571,492	247,231	230,727	299,871	374,016	394,884	224,259	226,143	228,110	169,659	270,843	270,809	187,006	125,000	125,000	125,000	125,000	4,500	5,200	2,912	3,500	5,552	5,552	241	296	76	83	91	97	103	111	100	26,100	100
Short Term Debt	493,877	493,398	8,294	9,251	10,375	9,226	10,611	10,829	10,464	9,659	11,024	11,227	11,754	374,290	370,100	365,964	361,882	10,225	10,165	9,210	0	374,230	369,752	365,326	360,949	-17,430	676,205	22,495	22,478	22,460	24,420	0	662,286	0	0	0	642,902	0	0	0	0	0	0	0	23,365	23,440	23,440	23,455	0	0	0	0	75,620	0	0	0	0	0	0	70,317	70,741	45,193	5,816	6,065	6,309	6,549	6,785	6,786	6,787	6,787	6,705	27,048	11,337	11,696	12,145	25,056	42,805	48,747	58,228	0	118,396	0	0	0	0	0	0	1,591	1,591	95	98	29	27	28	29	26	26	0	0	0
Short Term Investments	318,683	340,431	476,577	572,017	567,006	512,253	489,945	450,798	426,599	462,333	481,864	420,178	416,228	489,998	561,472	381,764	316,361	297,572	423,526	530,485	590,326	561,192	935,662	908,815	797,940	825,700	372,912	329,821	381,347	327,499	197,318	186,400	195,579	241,984	240,889	108,119	69,706	268,368	251,901	247,703	215,942	198,086	225,116	247,502	270,211	245,125	224,829	150,393	148,820	153,120	145,964	161,799	186,033	224,428	221,894	214,679	133,506	171,566	146,341	337,290	336,892	291,752	323,448	254,772	357,251	294,861	382,700	174,976	199,685	102,118	19,910	6,000	9,700	9,700	9,574	18,513	35,734	51,570	80,549	94,999	84,951	53,911	44,588	22,743	40,340	54,063	81,195	118,569	118,569	36,675	40,918	10,044	23,671	31,407	38,803	14,999	39,573	39,600	300	300
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	6,841,603	6,758,163	6,563,172	6,433,695	6,375,074	6,264,040	6,145,841	6,062,707	6,003,325	5,977,475	5,898,496	5,805,053	5,848,020	6,158,090	5,302,110	4,722,841	4,690,039	4,558,128	4,393,384	4,435,398	4,427,128	4,695,254	4,624,679	4,596,717	4,633,125	4,580,697	4,019,965	3,938,607	4,023,690	3,842,238	3,087,304	3,666,993	3,729,368	3,624,853	3,648,689	3,658,686	2,490,453	2,440,433	2,345,685	2,340,728	2,249,217	1,620,530	1,601,520	1,598,293	1,601,643	1,567,376	1,532,527	1,297,085	1,303,681	1,295,076	1,280,392	1,264,146	1,262,623	1,244,533	985,516	966,205	917,163	869,357	844,437	900,283	906,695	859,038	854,555	827,702	815,279	791,056	781,639	449,764	463,436	467,072	468,714	488,229	195,303	208,842	167,247	180,933	232,966	312,230	347,416	239,296	256,340	284,446	306,385	183,117	110,616	127,469	141,973	171,811	171,811	90,402	98,321	65,443	76,933	83,324	86,090	94,490	103,549	112,500	51,400	26,800
Total Current Assets	2,956,088	2,955,308	2,950,117	2,842,105	2,751,457	2,682,701	2,517,598	2,394,024	2,274,385	2,311,570	2,357,837	2,288,766	2,342,219	2,738,979	2,647,566	2,116,249	1,942,143	1,859,359	1,806,768	1,916,855	2,056,215	2,407,853	2,280,067	2,241,110	2,207,144	2,050,029	1,458,820	1,352,788	1,421,791	1,666,571	1,105,946	992,790	1,089,639	1,175,589	1,213,929	1,522,728	1,425,629	1,077,819	1,220,227	1,246,410	1,137,418	713,479	720,920	723,024	743,462	719,386	681,534	513,390	469,802	487,024	514,111	503,830	504,260	554,189	521,908	500,431	467,727	520,267	506,981	713,575	737,696	697,013	701,814	683,728	644,297	641,234	640,932	320,645	334,224	339,366	344,807	378,759	68,941	82,188	39,336	53,599	85,277	140,687	181,587	208,825	225,269	254,206	275,052	154,795	81,072	91,370	105,555	136,783	136,783	50,642	63,586	35,861	44,541	51,414	53,532	61,552	66,422	76,400	21,100	5,500
Total Current Liabilities	117,702	1,163,223	597,231	598,231	588,884	521,020	464,727	490,418	539,822	514,898	443,344	430,035	492,548	854,693	813,302	820,470	932,503	493,745	439,428	500,986	523,241	838,660	804,950	773,471	816,518	417,529	374,303	340,206	439,310	377,335	364,580	388,011	445,457	390,491	347,704	305,506	235,739	206,550	166,720	156,038	183,271	167,633	142,241	144,008	170,433	134,929	119,997	119,814	94,125	83,254	82,035	75,986	83,844	92,097	83,930	78,699	78,154	64,070	60,033	126,314	130,081	120,735	63,423	53,311	61,543	49,062	44,543	38,829	46,045	43,229	38,004	56,887	40,367	44,224	43,702	50,695	70,054	75,715	81,270	15,161	12,815	16,243	15,251	12,719	6,847	8,347	7,731	8,302	8,302	6,090	5,123	3,637	6,883	3,609	2,826	4,682	5,087	5,600	7,900	1,600
Total Liab	1,890,054	1,861,266	1,780,345	1,774,652	1,771,918	1,695,526	1,641,034	1,671,392	1,732,585	1,711,326	1,656,925	1,643,043	1,742,018	2,104,197	2,065,431	1,482,879	1,567,658	1,483,723	1,432,430	1,498,771	1,459,188	1,780,309	1,739,575	1,789,714	1,824,462	1,767,135	1,224,386	1,169,520	1,257,415	1,196,430	1,169,728	1,376,757	1,328,521	1,332,213	1,291,732	1,233,231	962,559	931,991	883,716	880,607	908,176	344,044	343,262	348,141	585,880	552,182	532,101	525,135	530,633	520,537	548,087	543,306	545,366	658,869	622,554	620,965	594,978	565,504	561,003	626,343	630,020	621,137	628,528	618,536	627,553	616,511	614,037	285,050	345,634	344,955	419,827	442,224	272,765	274,221	277,689	271,168	300,944	298,067	304,226	140,524	138,487	142,483	143,948	17,215	12,073	11,259	11,194	12,263	12,263	6,236	5,321	3,684	6,939	3,672	2,894	4,759	5,172	5,700	34,000	1,700
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	4,951,549	4,896,897	4,782,827	4,659,043	4,603,156	4,568,514	4,504,807	4,391,315	4,270,740	4,266,149	4,241,571	4,162,010	4,106,002	4,053,893	3,236,679	3,239,962	3,122,381	3,074,405	2,960,954	2,936,627	2,967,940	2,914,945	2,885,104	2,807,003	2,808,663	2,813,562	2,795,579	2,769,087	2,766,275	2,645,808	1,917,576	2,290,236	2,400,847	2,292,640	2,356,957	2,425,455	1,527,894	1,508,442	1,461,969	1,460,121	1,341,041	1,276,486	1,258,258	1,250,152	1,015,763	1,015,194	1,000,426	771,950	773,048	774,539	732,305	720,840	717,257	585,664	362,962	345,240	322,185	303,853	283,434	273,940	276,675	237,901	226,027	209,166	187,726	174,545	167,602	164,714	117,802	122,117	48,887	46,005	-77,462	-65,379	-110,442	-90,235	-67,978	14,163	43,190	98,772	117,853	141,963	162,437	165,902	98,543	116,210	130,779	159,548	159,548	84,166	93,000	61,759	69,994	79,652	83,196	89,731	98,377	106,800	17,400	25,100
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Begin Period Cash Flow	724,531	587,276	649,158	437,446	493,982	598,028	408,330	397,040	875,486	568,781	180,527	46,272	88,079	167,171	222,900	228,343	89,162	38,092	13,081	121,406	33,638	12,528	16,530	23,413	9,413	6,000
Capital Expenditures	107,611	131,540	119,225	137,519	163,406	144,620	199,219	148,380	227,653	118,834	65,124	44,571	154,219	49,461	89,801	56,368	22,413	24,583	2,957	24,075	5,975	4,861	17,812	3,760	22,944	6,400
Cash And Cash Equivalents Changes	0	0	-61,882	211,712	-56,536	-104,046	189,698	11,290	-478,446	306,705	388,254	134,255	-41,807	-79,092	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	23,167	-10,335	-36,617	-18,702	-23,126	-227,837	22,643	-8,646	-10,397	3,206	-89	4,893	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	30,596	137,255	-61,882	211,712	-56,536	-104,046	189,698	11,290	-478,446	306,705	388,254	134,255	-41,807	-79,092	-55,729	-5,443	139,181	51,070	25,011	-108,325	87,768	21,110	-4,002	-6,883	14,000	3,400
Change In Working Capital	-336,539	-96,383	66,034	-224,417	-101,092	-49,420	-93,963	-160,276	46,332	-30,340	-23,084	33,059	-25,099	-42,093	19,874	-88,987	-13,208	-29,522	7,503	4,263	-6,308	-1,966	-2,702	709	1,601	800
Change Receivables	0	0	65,574	-59,035	-37,852	-54,274	-25,256	0	-16,367	-26,650	-8,756	-4,227	-18,456	-13,036	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-190,435	-82,033	65,574	-59,035	-37,852	-54,274	-25,256	-51,483	-16,367	-26,650	-8,756	-4,227	-18,456	-13,036	-19,242	-37,322	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-157,058	-68,264	-35,060	-61,151	-107,554	-23,747	-96,890	-64,512	-50,989	-36,847	-33,910	1,423	-20,420	-31,036	-5,500	-13,938	-7,371	-14,177	-8,582	0	0	0	0	240	-5	-100
Change To Liabilities	0	59,018	12,353	-93,896	80,217	47,303	51,309	-53,205	90,298	41,803	29,979	43,445	12,071	4,066	0	7,433	11,648	10,399	0	14,907	6,168	0	0	1,795	0	0
Change To Netincome	0	28,755	185,242	-671,568	56,656	19,624	79,010	465,737	-141,219	26,815	86,759	38,345	59,353	-184,150	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	-5,104	19,831	-17,206	-32,775	-9,788	-17,334	8,924	23,390	-5,634	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	104,386	101,969	108,039	105,172	105,300	95,671	87,861	96,912	47,187	56,744	47,264	45,295	36,094	27,737	20,975	17,631	1,090	11,958	10,075	13,279	9,442	8,504	7,004	7,333	6,558	800
Dividends Paid	0	15,050	3,389	71,913	11,069	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	755,127	724,531	587,276	649,158	437,446	493,982	598,028	408,330	397,040	875,486	568,781	180,527	46,272	88,079	167,171	222,900	228,343	89,162	38,092	13,081	121,406	33,638	12,528	16,530	23,413	9,400
Exchange Rate Changes	0	0	-57	-1,150	902	-598	-3,231	-3,934	-5,072	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	51,648	44,362	185,311	-52,154	-115,144	-124,412	-207,976	-376,217	-449,342	-192,373	-124,758	-26,962	-135,466	-30,715	-2,069	-65,543	-56,908	-74,673	-65,637	-89,216	-80,773	-58,456	-40,877	-16,656	-35,884	-14,500
Investments	-100,991	-20,029	-366,313	26,171	108,188	358,981	-229,487	-484,047	-448,471	247,889	-107,284	-151,074	64,659	-18,931	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-2,605	-3,039	210,761	-5,087	-374,953	481,713	481,687	-163	-674	712,630	-678	-3,113	-14,279	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	167,645	141,561	-64,080	859,100	-23,848	-77,211	-117,042	-630,210	-171,799	-133,969	-176,353	-114,347	-53,836	205,819	-488	30,831	-15,803	-28,533	-74,270	-187,443	-76,375	-77,372	-57,428	-37,364	-28,072	-12,300
Other Cashflows From Financing Activities	-85,794	-16,045	2,991	613,027	-47,449	-13,054	507,145	14,170	39,819	68,899	760,243	77,470	34,007	33,644	9,999	29,403	309,350	155,419	22,305	-29,707	110,266	1,964	18,427	776	25,591	-8,200
Other Cashflows From Investing Activities	0	103,325	-24,641	34,520	5,812	49,990	123,247	-484,047	-951,945	65,500	-126,375	0	-81,000	-32,950	0	0	0	0	6,000	0	0	0	0	0	0	0
Other Non Cash Items	-206,830,252	-115,466	12,888	44,706	-9,203	-29,273	-70,340	559,150	-178,107	-28,724	35,514	16,183	13,322	19,498	2,045	-15	-6,574	-3,993	-5,988	104,760	-1,557	17,239	30,061	16,426	6,973	2,600
Sale Purchase Of Stock	0	-54,283	-45,805	-50,000	-42,680	67,488	60,859	787,165	951,302	197,368	66,182	316,901	33,592	33,103	0	0	0	0	0	0	8,615	0	0	0	0	0
Stock Based Compensation	207,099,000	196,308	197,263	189,711	159,865	148,819	140,263	134,641	111,525	88,233	66,181	47,340	43,909	38,362	36,005	28,336	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-18,727	-18,650	-48	181,118	-74,674	-388,007	507,145	727,108	927,913	185,689	746,671	312,291	29,000	3,504	-63,786	22,809	324,570	295,937	30,087	-27,894	213,468	3,849	152,990	7,567	95,690	19,700
Total Cash From Operating Activities	159,259	175,902	304,536	85,365	48,262	20,208	-8,757	-227,837	-221,689	-73,539	-59,634	17,609	18,753	18,746	87,732	-9,175	-34,495	-50,090	-62,680	-65,141	-74,798	-53,595	-23,065	-12,896	-12,940	-8,100
Total Cashflows From Investing Activities	0	-20,029	-366,313	-53,621	-31,026	264,351	-305,459	-484,047	-1,179,598	194,555	-298,783	-195,645	-89,560	-101,342	0	0	0	0	54,603	0	0	70,910	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31
Begin Period Cash Flow	785,414	694,381	580,074	724,531	761,515	619,802	605,440	587,276	617,143	641,533	667,313	649,158	1,015,675	818,900	476,632	437,446	423,220	307,577	364,369	493,982	882,184	427,411	473,980	598,028	431,399	354,864	348,234	408,330	707,349	305,969	270,453	397,040	376,346	440,664	900,570	875,486	398,005	584,717	639,778	568,781	181,565	175,445	154,380	180,527	181,330	177,757	82,586	46,272	71,254	112,956	90,782	88,079	127,539	115,779	108,963	167,171	191,778	200,050	214,579	222,900	271,217	252,209	319,990	228,343	291,825	205,010	98,331	89,162	191,782	285,990	341,689	38,092	56,213	17,111	11,246	13,081	34,981	48,247	96,199	121,406	187,978	221,772	125,835	33,638	32,405	19,363	18,202	7,230	7,230	18,967	19,722	16,530	16,098	10,609	40,675	23,413	32,600	17,200	3,600	9,400
Capital Expenditures	36,696	23,419	22,730	24,766	36,359	36,471	28,035	30,675	44,359	20,360	26,252	28,254	39,864	20,153	33,485	44,017	60,842	35,407	38,401	28,756	42,079	49,859	22,518	30,164	39,890	42,482	47,757	69,090	51,574	26,096	25,506	45,204	103,809	44,556	35,456	43,832	29,206	24,919	40,532	24,177	29,684	13,202	10,412	11,826	13,895	15,013	9,484	6,179	89,680	56,388	1,910	6,241	10,741	9,372	15,240	14,108	22,621	26,559	21,884	18,737	11,923	12,113	12,443	19,889	9,937	5,648	3,593	3,235	3,217	2,469	18,028	869	1,410	512	453	582	7,674	10,748	4,421	1,232	3,338	1,865	602	170	475	500	2,641	6,911	6,911	6,315	4,156	430	1,798	687	667	608	3,844	7,300	9,000	2,800
Cash And Cash Equivalents Changes	0	0	111,555	-144,686	0	142,460	13,654	18,164	-29,867	-24,390	-25,780	18,155	-366,517	196,775	342,268	39,186	0	0	-56,792	-129,613	-388,202	454,773	-46,569	-124,048	166,629	76,535	6,630	-60,096	-299,019	401,380	35,516	-126,587	20,694	-64,318	-459,906	25,084	477,481	-186,712	-55,061	70,997	387,216	6,120	21,065	-26,147	-803	3,573	95,171	36,314	-24,982	-41,702	22,174	2,703	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-10,072	-36,324	0	6,434	3,719	-6,571	-3,455	-8,030	-9,749	44,401	-37,640	12,463	6,981	7,861	0	0	-21,914	12,332	-19,830	9,613	-10,310	1,825	-1,309	-16,998	-7,055	2,236	-221,279	-8,305	580	1,167	52,004	-32,069	5,900	-3,192	7,855	-14,966	347	-1,882	-8,314	4,661	-2,075	-4,669	21,590	5,969	-2,019	-22,334	8,338	-2,294	-5,730	-403	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-30,287	91,033	114,307	-144,457	-36,984	141,713	14,362	18,164	-29,867	-24,390	-25,780	18,155	-366,517	196,775	342,268	39,186	14,226	115,643	-56,792	-129,613	-388,202	454,773	-46,569	-124,048	166,629	76,535	6,630	-60,096	-299,019	401,380	35,516	-126,587	20,694	-64,318	-459,906	25,084	477,481	-186,712	-55,061	70,997	387,216	6,120	21,065	-26,147	-803	3,573	95,171	36,314	-24,982	-41,702	22,174	2,703	-39,460	11,760	6,816	-58,208	-24,607	-8,272	-14,529	-8,321	-48,317	19,008	-67,781	91,647	-63,482	86,815	106,679	9,169	-102,620	-94,208	-55,699	303,597	-18,121	39,102	5,865	-1,835	-21,900	-13,266	-47,952	-25,207	-66,572	-33,794	95,937	92,197	1,233	13,042	1,161	5,298	5,298	-11,737	-755	3,192	432	5,489	-30,066	17,262	-9,187	15,400	13,600	-5,800
Change In Working Capital	-97,116	39,919	-62,700	-216,642	-13,144	91,527	-38,074	-136,692	-116	67,998	-10,118	8,270	-78,548	-17,898	6,361	-134,332	9,520	-9,589	-22,804	-78,219	63,914	-12,600	-34,850	-65,884	28,572	-7,686	-5,296	-109,553	40,410	-13,852	-64,796	-122,038	135,813	10,395	2,101	-101,977	196	13,483	-16,875	-27,144	-2,063	10,999	-236	-31,784	26,826	6,895	6,215	-6,877	4,871	-3,712	-4,171	-22,087	-27,676	-5,900	4,956	-13,473	2,470	5,566	752	11,086	-37,275	-12,060	-8,025	-31,627	1,939	-2,415	-2,249	-10,483	-1,617	-7,554	-8,727	-11,624	-4,557	-7,216	17,272	2,004	2,938	3,188	-5,585	3,722	-9,774	-2,376	-330	6,172	-3,194	157	1,254	1,509	83,929	-2,159	3,101	-5,153	3,474	992	-189	-3,568	901	-3,000	2,700	1,000
Change Receivables	0	0	-7,035	-138,796	0	38,810	-37,749	-54,813	61	48,093	-22,874	40,294	-26,120	-24,887	23,870	-31,898	0	0	20,660	-51,690	41,610	-18,468	-51,159	-26,257	-3,658	-4,764	-2,783	-14,051	0	-1,773	-34,206	-16,044	-16,513	37,733	-10,798	-26,789	-23,077	887	-11,820	7,360	6,923	-9,682	5,282	-11,279	8,224	-16,540	5,078	-989	2,025	-451	-408	-19,622	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-58,495	13,891	-7,035	-138,796	-28,281	38,810	-37,749	-54,813	61	48,093	-22,874	40,294	-26,120	-24,887	23,870	-31,898	23,951	-30,773	20,660	-51,690	41,610	-18,468	-51,159	-26,257	-3,658	-4,764	-2,783	-14,051	540	-1,773	-34,206	-16,044	-16,513	37,733	-10,798	-26,789	-23,077	887	-11,820	7,360	6,923	-9,682	5,282	-11,279	8,224	-16,540	5,078	-989	2,025	-451	-408	-19,622	-7,842	-1,052	4,924	-9,066	-5,162	4,198	-11,221	-7,057	0	0	0	-30,277	0	0	0	145	0	0	0	-1,633	0	0	1,177	2,216	0	0	0	0	0	0	0	0	0	464	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-59,110	-41,472	-42,378	-14,098	-40,845	-25,988	-2,556	1,125	-15,935	-25,504	12,804	-6,425	12,159	-27,012	-25,592	-20,706	-54,983	-19,452	-34,854	1,735	-13,515	-25,725	4,650	10,843	-16,005	-20,516	-37,709	-22,660	-4,710	-17,089	-30,910	-11,803	10,991	-23,546	-14,488	-23,946	4,992	-10,946	-16,605	-14,288	-13,921	-6,388	-6,474	-7,127	-7,870	-700	3,939	6,054	-14,490	-3,329	-2,232	-369	-17,957	-7,963	-4,017	-1,099	-3,221	-2,605	3,586	-3,260	-5,069	-6,293	-7,050	4,474	-895	-837	-3,276	-2,363	687	-1,515	-6,109	-7,240	-3,178	-4,334	-947	-123	0	-1,017	227	0	0	0	0	0	0	0	0	0	0	-45	-41	-3	10	49	152	29	895	0	0	0
Change To Liabilities	0	81,426	9,435	-27,424	61,416	73,947	-1,488	-76,433	19,213	53,755	11,420	-70,000	-26,947	21,538	1,102	-89,589	55,342	59,318	13,304	-40,596	55,649	21,980	21,969	-52,295	49,544	34,592	42,251	-75,078	-53,205	13,315	-260	-95,358	90,298	28,277	21,487	-48,050	10,426	38,508	11,203	-18,334	13,249	22,408	-1,720	-3,958	18,995	18,783	456	5,211	9,593	4,596	-474	-1,644	2,039	0	0	0	0	620	0	0	7,433	947	4,442	0	11,648	451	0	0	10,399	8,398	2,271	0	0	0	0	0	14,907	8,107	3,129	2,752	6,168	9,469	8,193	5,539	0	0	0	854	0	0	0	0	1,795	0	0	0	0	0	0	0
Change To Netincome	0	29,664	40,187	66,378	-4,374	48,644	38,918	-59,565	40,300	38,717	52,730	58,172	13,570	-712,702	20,449	7,115	7,009	-6,061	5,715	53,879	-40,282	36,466	-11,089	34,529	-653	28,779	33,311	17,573	435,793	10,064	415,849	15,074	-274,909	61,279	51,191	16,853	24,538	-45,511	23,326	24,462	41,742	17,834	5,389	21,794	10,808	-945	11,073	17,409	10,485	17,640	17,983	13,245	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	-13,926	-13,926	-32,062	-5,434	4,758	433	-4,861	-7,060	-8,346	-11,468	46,705	-53,736	15,750	7,775	13,005	-14,790	-18,682	-13,109	13,806	-14,660	10,694	-7,239	1,417	-17,334	-16,960	-6,340	2,236	8,924	-8,305	580	0	23,390	0	0	0	-5,634	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	26,861	25,685	25,419	26,421	24,553	24,802	25,271	27,343	25,986	26,839	27,231	27,983	27,358	26,634	25,216	25,964	25,790	30,739	26,344	22,427	24,716	26,345	20,977	23,633	28,664	20,700	19,085	19,412	20,107	28,309	28,252	20,244	1,881	15,727	15,182	14,397	16,823	14,220	13,678	12,023	9,384	13,375	12,941	11,564	11,857	11,667	11,173	10,598	9,628	9,350	8,531	8,585	7,931	7,819	6,577	5,410	4,861	5,182	5,829	5,103	10,226	3,367	3,007	1,031	260	-149	136	843	2,561	3,086	3,776	2,535	2,775	2,429	2,405	2,466	599	6,208	4,221	2,251	2,385	2,932	2,040	2,085	1,884	2,381	2,178	839	839	2,203	2,062	1,900	1,995	1,907	1,697	1,734	2,358	2,000	1,200	1,000
Dividends Paid	0	4,537	16,440	51,422	21,880	8,054	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	755,127	785,414	694,381	580,074	724,531	761,515	619,802	605,440	587,276	617,143	641,533	667,313	649,158	1,015,675	818,900	476,632	437,446	423,220	307,577	364,369	493,982	882,184	427,411	473,980	598,028	431,399	354,864	348,234	408,330	707,349	305,969	270,453	397,040	376,346	440,664	900,570	875,486	398,005	584,717	639,778	568,781	181,565	175,445	154,380	180,527	181,330	177,757	82,586	46,272	71,254	112,956	90,782	88,079	127,539	115,779	108,963	167,171	191,778	200,050	214,579	222,900	271,217	252,209	319,990	228,343	291,825	205,010	98,331	89,162	191,782	285,990	341,689	38,092	56,213	17,111	11,246	13,081	34,981	48,247	96,199	121,406	187,978	221,772	125,835	33,638	32,405	19,363	12,528	12,528	7,230	18,967	19,722	16,530	16,098	10,609	40,675	23,413	32,600	17,200	3,600
Exchange Rate Changes	0	0	0	0	0	0	0	1,093	-22	-572	742	-205	1,995	614	-406	-3,353	0	0	-365	715	-251	96	-403	-40	-627	-13,464	8,817	2,043	-9,073	1,680	-1,673	5,132	-2,528	-2,153	634	-1,025	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-9,213	112,227	47,332	-98,698	-29,573	121,850	28,191	-76,106	-33,179	76,700	56,532	85,258	-53,248	66,053	-5,748	-59,211	-3,499	34,718	-62,739	-83,624	7,295	-2,659	-56,375	-72,673	-25,276	-4,190	-28,977	-149,533	-51,221	-36,713	-71,526	-216,757	-171,846	-47,406	-48,447	-181,643	-55,983	-33,275	-52,064	-51,051	-40,980	-22,694	-17,229	-43,855	-1,909	-799	-10,904	-13,350	-89,855	-47,527	11,656	-9,740	-26,523	-315	6,981	-10,858	-3,155	2,516	-2,713	1,283	-7,956	-10,228	-5,250	-42,109	-7,873	-15,381	-10,293	-23,361	-13,949	-15,015	-25,465	-20,244	-20,080	-22,595	-3,977	-18,985	-17,139	-30,830	-25,983	-15,264	-36,324	-24,504	-7,979	-11,966	-34,674	-5,651	-7,553	-12,574	-12,574	-12,401	-6,318	-9,584	-4,667	-2,351	-3,187	-6,451	-6,984	-14,000	-8,000	-6,900
Investments	-64,963	-45,799	29,530	-5,246	-54,710	-23,402	-1,664	8,457	-55,421	-99,401	-93,097	-42,534	50,889	126,855	-206,170	54,597	-48,896	48,678	57,106	-19,949	-58,884	451,354	7,982	-41,471	54,629	-387,747	8,103	95,528	-332,180	-292,458	102,513	122,203	132,616	-6,024	-410,769	-167,620	490,451	-228,808	1,161	-14,915	-160,232	16,515	22,672	13,761	-38,458	-5,934	-142,899	36,217	54,766	-1,933	2,616	9,210	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-606	-606	-1,014	-970	-513	-556	-566	-547	-551	-857	-1,084	-374,991	-30	585,782	-943	-5,087	-5,087	-5,087	-5,087	-374,953	-374,953	-374,953	0	481,713	481,713	481,713	481,713	481,713	0	0	0	481,713	0	0	-163	481,713	0	-657	-17	725,310	-1,876	-143	-10,661	-143	-142	-143	-250	-355	-2,287	-156	-315	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	20,375	40,378	56,040	50,852	-249	-6,652	27,664	120,798	-57,898	-36,494	12,941	17,371	22,099	784,803	-29,183	81,381	15,024	55,036	-37,435	-56,473	-3,650	-12,620	-16,792	-44,149	-51,392	-12,527	-36,833	-16,290	-78,711	-42,797	-423,560	-85,142	68,617	-90,926	-81,989	-67,501	-69,797	7,445	-33,502	-38,115	-61,990	-53,020	-21,533	-39,810	-53,012	-5,357	-32,006	-23,972	-26,735	-17,653	-5,077	-4,371	-12,189	217,334	-477	1,151	4,711	6,641	1,312	-13,152	24,506	829	3,810	1,686	2,570	-5,216	-3,864	-9,293	-10,391	-7,036	-1,326	-9,780	-14,996	-15,476	-21,340	-22,458	-82,422	-29,478	-55,598	-19,945	-25,727	-21,291	-9,097	-20,260	-19,325	-16,890	-14,573	-24,744	-34,922	-11,015	-11,969	-9,700	-10,394	-8,148	-7,086	-11,736	-9,072	-7,600	8,300	-19,700
Other Cashflows From Financing Activities	-3,920	4,537	16,440	41,947	11,839	8,054	-11,224	-24,714	14,943	-480	11,808	-23,280	9,674	7,289	564,792	-18,728	4,042	-1,975	-51,760	-24,981	-366,362	5,151	-17,031	-9,765	13,096	481,936	18,856	-6,743	19,350	24,316	7,669	-37,165	11,708	3,765	-2,351	26,697	43,012	8,871	-2,501	19,517	705,820	14,175	15,765	24,483	39,707	37,679	66	18	10,462	81	8,058	3,548	13,724	12,971	-2,234	9,183	-26,946	5,376	1,923	895	27,809	-1,500	-1,750	-1,750	-1,740	-1,750	314,590	-1,750	-1,750	-1,705	-22,124	181,963	54,204	-2,218	-15,108	-1,049	-21,143	-11,757	3,896	-703	-9,310	-201	120,139	-362	1,336	633	498	18,476	18,476	-35	-7	-7	-113	903	-6	-8	25,591	70,700	24,900	-1,700
Other Cashflows From Investing Activities	0	0	-1,147	-310	-6,675	-7,171	-881	108,142	-15,621	-86	-908	-2,747	-8,836	-3,586	-16,419	63,361	939	-939	-4,804	-1,774	30,000	831	19,258	-99	124,807	0	-169	-1,391	-474,047	-8,383	-1,617	0	50,744	-12,500	1,027	-539,419	13,212	66,500	-1,000	0	-116,500	0	0	-9,875	0	0	0	0	-81,000	0	0	0	0	0	0	0	0	0	0	0	0	818	0	0	0	0	10,774	0	0	0	0	0	6,000	6,000	4,000	2,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	47,352	-3,694	-111	18,102	236	-1,821	-4,368	-109,513	2,905	2,915	18	7,050	2,829	90,833	-3,152	-45,804	-8,113	4,463	-20,893	15,340	-36,521	12,082	-26,105	21,271	-105,429	15,282	14,052	5,755	2,489	6,775	545,403	4,483	-209,952	2,305	28,184	1,356	6,129	-56,316	12,189	9,274	9,774	11,854	-2,650	16,536	13,700	-228	1,498	1,213	3,354	9,241	414	313	13,829	-6,148	687	1,792	-2,771	2,532	2,318	8,449	6,510	9,028	8,401	5,049	-2,705	-1,953	-723	3,815	-1,285	-1,042	-1,160	-506	-1,892	-1,820	-1,861	-415	69,420	0	35,400	-60	130	-1,904	10	207	-13,564	8,201	6,229	16,733	0	4,885	4,644	3,799	2,056	3,585	3,058	7,727	2,673	1,900	-11,200	13,600
Sale Purchase Of Stock	0	-4,537	-16,440	-51,422	-3,587	-6,319	-11,428	8,235	16,317	5,237	21,823	5,817	11,645	-50,000	-13,189	10,116	31,611	21,768	13,215	5,798	11,845	10,717	31,792	13,134	14,740	5,460	27,573	13,086	24,729	712,938	19,493	3,521	11,530	6,088	17,401	916,283	42,270	9,533	8,390	137,175	12,094	14,293	15,440	24,355	43,735	10,436	249,051	13,679	10,156	11,858	8,445	3,133	0	0	0	0	0	190	118	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8,615	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	54,855	48,387	50,162	53,695	46,734	54,663	47,078	47,833	43,891	49,026	54,843	49,503	47,586	50,169	44,962	46,994	38,102	39,173	39,829	42,761	36,558	37,047	38,606	36,608	33,585	35,903	40,101	30,674	37,421	33,145	33,898	30,177	27,060	30,069	30,682	23,714	32,982	20,463	17,521	17,267	23,543	16,790	14,340	11,508	11,926	11,990	12,269	11,155	11,188	11,784	10,786	10,151	9,835	10,294	9,627	8,606	9,356	9,155	8,960	8,534	0	34	0	5,210	0	0	0	3,815	0	0	0	2,104	0	0	0	0	0	0	0	0	0	-3,569	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	10,840	-788	11,963	-40,742	10,869	7,541	-11,780	-25,280	14,396	-1,031	10,951	-24,364	-366,155	3,256	563,688	-19,671	4,042	-1,975	-51,760	-24,981	-366,362	5,151	-17,031	-9,765	13,096	481,936	18,856	-6,743	19,350	737,254	7,669	-37,165	11,708	3,765	-2,351	914,791	43,013	8,871	-3,158	136,963	704,928	12,299	15,622	13,822	39,564	10,306	248,974	13,447	10,107	7,758	7,902	3,233	-10,068	6,708	-2,276	9,140	1,448	5,521	-70,102	-653	2,414	2,372	5,518	12,505	3,306	4,908	316,666	-310	1,097	2,990	-20,290	312,140	459	58,194	-14,066	-14,500	-20,346	-11,662	4,010	104	785	298	125,819	86,566	1,825	1,393	759	106,810	106,810	1,937	42,994	1,249	331	4,249	174	2,813	90	70,700	24,900	0
Total Cash From Operating Activities	27,483	135,646	70,062	-73,932	6,786	158,321	56,226	-45,431	11,180	97,060	82,784	113,512	-13,384	86,206	27,737	-15,194	57,343	70,125	-24,338	-54,868	49,374	47,200	-33,857	-42,509	14,614	38,292	18,780	-80,443	353	-10,617	-46,020	-171,553	-68,037	-2,850	-12,991	-137,811	-26,777	-8,356	-11,532	-26,874	-11,296	-9,492	-6,817	-32,029	11,986	14,214	-1,420	-7,171	-175	8,861	13,566	-3,499	-15,782	9,057	22,221	3,250	19,466	29,075	19,171	20,020	3,967	1,885	7,193	-22,220	2,064	-9,733	-6,700	-20,126	-10,732	-12,546	-7,437	-19,375	-18,670	-22,083	-3,524	-18,403	-9,465	-20,082	-21,562	-14,032	-32,986	-22,639	-7,377	-11,796	-34,199	-6,151	-4,912	-5,663	-5,663	-6,086	-2,162	-9,154	-2,869	-1,664	-2,520	-5,843	-3,140	-6,700	1,000	-4,100
Total Cashflows From Investing Activities	0	-45,799	29,530	-30,012	-54,710	-23,402	-29,699	87,782	-55,421	-119,847	-120,257	-70,788	11,027	106,699	-248,751	77,404	-48,896	48,678	19,671	-50,479	-70,963	402,326	4,722	-71,734	139,546	-430,229	-39,823	25,047	-309,649	-326,937	75,540	76,999	79,551	-63,080	-445,198	-750,871	461,245	-187,227	-40,371	-39,092	-306,416	3,313	12,260	-7,940	-52,353	-20,947	-152,383	30,038	-34,914	-58,321	706	2,969	-101,342	-87,732	-83,727	0	0	0	8,713	0	0	35,621	20,870	101,362	0	0	0	23,604	0	0	0	2,831	54,603	56,013	54,524	31,069	0	0	0	0	0	0	0	17,416	70,910	37,306	19,478	14,196	0	0	0	11,097	0	0	0	20,292	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Cost Of Revenue	577,065	483,669	470,515	524,272	359,466	315,264	241,786	209,620	152,008	129,764	95,742	91,830	84,023	70,285	65,909	52,509	18,359	8,740	2,629	3,953	62,212	64,196	45,828	-6,614	-6,094	-700
Depreciation And Amortization	104,386	101,969	108,039	90,410	103,214	48,791	46,471	-26,953	-17,690	17,968	47,264	18,717	36,094	27,737	2,914	4,371	1,090	11,958	10,075	13,279	9,442	8,504	7,004	7,333	6,558	800
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	157,597	57,546	-60,013	-96,260	-125,457	-149,041	-118,168	-165,480	-269,588	-155,726	-166,056	-110,639	-68,048	-19,666	18,919	49,818	-54,007	-24,673	-64,213	-48,208	-57,110	-46,854	-28,655	-25,666	-25,826	-13,500
Ebitda	261,983	159,515	48,026	-5,850	-22,243	-100,250	-71,697	-192,433	-287,278	-137,758	-118,792	-91,922	-31,954	8,071	21,833	54,189	-52,917	-12,715	-54,138	-34,929	-47,668	-38,350	-21,651	-18,333	-19,268	-12,700
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	-42,300	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	1,842,161	1,612,370	1,375,760	1,336,183	1,344,582	1,175,948	1,071,860	907,234	737,887	621,276	452,743	408,893	357,335	305,982	258,747	243,984	103,222	75,469	23,040	14,688	12,100	13,919	11,699	18,940	13,070	1,900
Income Before Tax	188,563	149,576	-75,350	-42,322	-94,811	-142,705	-35,875	-831,050	-154,724	-124,868	-176,503	-118,278	-43,627	-21,490	566	33,424	-15,074	-28,533	-74,270	-187,443	-75,798	-77,461	-70,929	-40,336	-29,172	-12,300
Income Tax Expense	20,918	8,015	-11,270	-901,422	-70,963	-65,494	81,167	-200,840	17,075	9,101	-150	-3,931	10,209	-227,309	1,054	2,593	729	23,134	21,895	36,559	-5	9,837	19,971	4,363	573	-600
Interest Expense	17,335	15,970	15,337	29,309	23,460	43,664	42,707	39,499	38,244	36,642	10,447	7,639	8,349	10,329	14,090	16,394	14,243	16,726	11,918	10,544	3,131	542	0	7	0	0
Interest Income	49,005	18,034	10,482	16,610	22,748	22,831	14,853	7,487	34,560	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	167,645	141,561	-64,080	854,029	-23,848	-77,211	-117,042	-630,210	-171,799	-133,969	-176,353	-114,347	-53,836	205,819	-488	30,831	-15,803	-28,533	-74,270	-187,443	-75,798	-77,461	-67,606	-37,364	-28,072	-12,300
Net Income Applicable To Common Shares	0	141,561	-64,080	859,100	-23,848	-77,211	-117,042	-630,210	-171,799	-133,969	-176,353	-114,347	-53,836	205,819	0	30,831	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	147,021	141,561	-64,080	859,100	-23,848	-77,211	-117,042	-630,210	-171,799	-133,969	-176,353	-114,347	-53,836	205,819	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	34,142	2,064	-4,855	-12,699	-712	-20,833	-27,854	-32,012	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	10,482	16,604	22,161	22,278	13,562	6,949	3,521	4,386	-11,031	1,363	-1,388	-11,705	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	599,118	198,700	198,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	157,597	57,546	-60,013	-96,260	-125,457	-123,524	-14,700	-803,429	-110,702	-92,891	-156,007	-110,215	-33,890	544	16,427	39,756	-57,288	-24,673	-64,213	-179,365	-75,803	-78,847	-51,949	-33,001	-27,499	-12,900
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	2,261,629	2,054,477	1,928,616	1,956,715	1,829,505	1,664,736	1,453,346	1,321,165	1,171,395	911,431	704,492	610,938	473,820	369,317	308,229	256,737	178,869	108,882	89,882	166,553	87,903	81,543	52,001	45,327	34,475	14,100
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	102,078	101,969	108,039	105,172	105,300	95,671	87,861	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Research Development	746,773	649,606	628,793	628,116	715,007	696,328	610,753	661,905	634,806	461,543	354,780	302,218	214,374	147,309	115,116	93,291	78,600	66,735	56,391	49,784	54,814	54,455	45,283	35,794	27,206	10,500
Selling And Marketing Expenses	488,400	450,300	405,100	403,400	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	448,900	403,709	354,300	334,300	680,924	604,353	554,336	476,593	402,271	302,156	235,356	198,173	175,423	151,723	124,290	106,566	77,539	49,030	41,556	37,606	14,396	17,541	6,718	8,814	6,805	3,500
Tax Provision	4,657	8,015	-11,270	-901,422	-70,963	-65,494	81,167	-200,840	17,075	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	1,684,564	1,570,808	1,458,101	1,432,443	1,470,039	1,349,472	1,211,560	1,111,545	1,019,387	781,667	608,750	519,108	389,797	299,032	242,320	204,228	160,510	100,142	87,253	162,600	87,903	81,543	52,001	51,941	40,569	14,800
Total Other Income Expense Net	30,966	92,030	-15,337	53,938	30,646	51,652	131,679	-594,727	160,682	66,902	-167	-3,008	-5,750	-22,223	-6,857	-6,326	30,525	19,274	11,838	-102,676	-18,693	-20,770	-18,980	-7,335	-1,673	600
Total Revenue	2,419,226	2,096,039	1,846,275	1,860,455	1,704,048	1,491,212	1,313,646	1,116,854	889,895	751,040	548,485	500,723	441,358	376,267	324,656	296,493	121,581	84,209	25,669	18,641	12,100	13,919	11,699	12,326	6,976	1,200

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31
Cost Of Revenue	135,478	140,426	143,682	142,249	127,290	116,288	123,126	116,965	119,750	103,537	127,062	120,166	126,138	188,793	97,967	111,374	95,899	96,949	77,436	89,182	75,019	78,893	79,019	82,333	75,995	59,480	56,305	50,006	64,147	50,738	51,617	43,118	48,044	36,719	39,878	32,813	45,818	29,920	31,210	22,816	24,621	28,054	22,567	20,500	26,532	24,619	23,574	17,105	21,519	22,445	19,263	20,796	20,469	18,003	14,401	17,412	16,729	14,970	19,848	14,362	11,665	14,063	9,593	17,188	5,224	4,460	4,557	4,117	3,616	2,612	789	1,722	1,328	164	478	660	3,305	35	613	15,576	20,547	15,139	14,074	11,705	11,685	9,095	14,874	0	15,427	281	308	-1,629	-1,815	-1,713	-1,533	-1,553	-2,194	-1,900	-1,100	-800
Depreciation And Amortization	26,861	25,685	25,419	26,421	24,553	24,802	24,829	27,343	25,986	26,839	27,231	27,983	18,640	17,429	14,912	15,677	16,994	17,063	20,286	19,765	6,782	18,580	10,227	13,202	20,375	3,760	19,085	19,412	7,365	9,654	-54,414	10,442	-40,654	1,301	15,470	1,431	1,956	2,934	3,668	8,957	9,384	9,639	-2,022	5,556	12,898	11,667	11,173	10,598	9,628	9,350	8,531	312	7,931	3,972	1,580	654	4,861	46	5,829	5,103	10,226	3,367	3,007	1,031	260	-149	136	843	2,561	3,086	3,776	2,535	2,775	2,429	2,405	2,466	599	6,208	4,221	2,251	2,385	2,932	2,040	2,085	1,884	2,381	2,178	839	839	2,203	2,062	1,900	1,995	1,907	1,697	1,734	2,358	2,000	1,200	1,000
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	14,219	22,830	56,771	60,466	-13,932	2,775	39,152	29,993	-62,728	-42,290	17,973	27,032	-35,436	-51,619	-34,225	48,772	-12,851	12,759	-50,029	-46,230	-65,565	-7,282	-36,952	-39,242	-58,738	-9,737	-36,392	-15,073	-82,434	-56,833	80,531	-79,283	-27,846	-80,996	-72,542	-65,241	-56,540	-55,161	-18,507	-25,518	-51,782	-51,790	-17,666	-42,796	-48,164	-20,273	-39,441	-30,365	-21,440	-21,713	-7,632	2,534	-3,228	-1,610	3,214	3,289	6,596	10,465	4,653	-2,795	42,118	2,351	4,530	880	-8,537	-16,259	-12,644	-16,565	-11,563	-801	-1,337	-7,658	-12,826	-13,174	-18,774	-24,429	-18,421	-26,622	17,045	-19,335	-25,113	-20,670	-9,477	-17,286	-23,813	-12,696	-10,514	-3,964	-10,903	-7,809	-8,932	-7,950	-8,957	-7,657	-6,490	-2,562	-8,426	-7,300	-5,700	-20,100
Ebitda	41,080	48,515	82,190	86,887	10,621	27,577	63,981	57,336	-36,742	-15,451	45,204	55,015	-16,796	-34,190	-19,313	64,449	4,143	29,822	-29,743	-26,465	-58,783	11,298	-26,725	-26,040	-38,363	-5,977	-17,307	4,339	-75,069	-47,179	26,117	-68,841	-68,500	-79,695	-57,072	-63,810	-54,584	-52,227	-14,839	-16,561	-42,398	-42,151	-19,688	-37,240	-35,266	-8,606	-28,268	-19,767	-11,812	-12,363	899	2,846	4,703	2,362	4,794	3,943	11,457	10,511	10,482	2,308	52,344	5,718	7,537	1,911	-8,277	-16,408	-12,508	-15,722	-9,002	2,285	2,439	-5,123	-10,051	-10,745	-16,369	-21,963	-17,822	-20,414	21,266	-17,084	-22,728	-17,738	-7,437	-15,201	-21,929	-10,315	-8,336	-3,125	-10,064	-5,606	-6,870	-6,050	-6,962	-5,750	-4,793	-828	-6,068	-5,300	-4,500	-19,100
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	510,729	445,539	450,916	450,696	410,248	389,056	410,672	402,394	330,060	305,205	374,631	365,864	325,979	287,991	331,518	390,695	358,544	364,148	310,327	311,563	278,195	312,813	293,826	291,114	282,310	274,668	261,143	253,739	235,944	229,158	248,514	193,618	179,892	172,185	210,645	170,451	185,036	146,927	160,577	128,736	122,252	108,820	114,243	107,428	105,406	103,498	100,445	99,544	86,327	90,980	91,368	88,660	81,145	79,747	77,549	67,541	70,353	65,837	62,939	59,618	87,611	58,583	54,581	43,208	39,630	20,546	24,327	18,721	18,403	22,315	22,661	12,090	8,147	7,415	3,148	4,329	10,592	146	3,950	0	-15,596	0	12,100	3,496	3,135	3,569	3,423	891	0	3,463	3,356	5,029	4,953	4,520	4,616	4,851	4,470	3,900	2,700	3,100
Income Before Tax	19,327	41,669	70,810	56,757	-17,558	-1,904	34,851	134,187	-66,574	-46,160	14,156	23,228	-40,185	-61,216	-42,273	101,352	-9,781	9,822	-41,895	-52,957	-43,311	-19,413	-29,177	-50,804	54,598	-20,621	-45,546	-24,306	-92,166	-66,813	-582,945	-89,126	92,965	-90,443	-82,544	-74,703	-65,737	3,221	-27,728	-34,624	-59,375	-52,316	-20,291	-44,521	-50,094	-11,761	-32,417	-24,006	-23,116	-19,731	-1,173	393	-19,238	-4,618	579	1,787	3,881	7,585	1,834	-12,735	26,556	1,081	3,960	1,824	-15,074	-5,216	-3,864	-9,293	-187,443	-7,036	-1,325	-9,780	-75,798	-15,476	-21,340	-22,458	105,021	-29,478	-55,598	-19,945	-67,606	-21,291	-9,097	-19,683	-37,364	-17,396	-15,436	-36,822	0	-11,537	-12,404	-10,166	-11,091	-8,837	-7,886	-12,522	-9,772	-8,300	-6,500	-20,500
Income Tax Expense	-1,048	1,291	14,770	5,905	-17,309	4,748	7,187	13,389	-8,676	-9,666	1,215	5,857	-62,284	-846,019	-13,090	19,971	-24,805	-45,214	-4,460	3,516	-39,661	-6,793	-12,385	-6,655	105,990	-8,094	-8,713	-8,016	-1,446	-24,016	-159,385	-3,984	24,348	483	-555	-7,202	4,060	-4,224	5,774	3,491	2,615	704	1,242	-4,711	2,918	-6,404	-411	-34	3,619	-2,078	3,904	4,764	-7,049	-221,952	1,056	636	-830	945	522	417	2,050	252	153	138	729	-2,597	-2,230	-1,109	-18,141	7,979	4,733	5,922	-59,274	5,690	5,869	105	734	2,349	35,500	-1,149	-50,071	-3,882	-5,766	-860	-58,123	2,063	1,436	16,686	0	1,342	1,301	642	370	-99	-102	4,194	-27	-200	700	-600
Interest Expense	6,098	3,779	3,755	3,703	3,626	4,679	3,859	3,806	3,846	3,870	3,817	3,804	4,749	9,597	8,048	6,915	6,930	2,937	6,866	6,727	7,746	12,131	12,225	11,562	11,664	10,884	9,154	9,233	9,732	9,980	9,944	9,843	9,333	9,447	10,002	9,462	9,197	9,118	9,221	9,106	7,593	526	603	1,725	1,930	1,837	1,925	1,947	1,704	2,432	2,072	2,141	2,257	3,008	2,635	2,429	2,715	2,880	4,404	4,087	17,516	4,105	4,081	4,110	17,963	4,109	3,720	2,335	6,271	3,608	4,022	2,821	2,854	2,863	2,940	3,259	1,371	3,429	2,418	1,371	1,386	1,402	213	130	168	107	161	91	6	8	1	2	1	2	2	2	0	0	0	0
Interest Income	18,044	15,740	12,612	11,943	8,710	4,999	2,505	1,820	1,745	1,827	4,471	2,439	3,071	4,004	4,291	5,244	5,211	5,340	5,899	614	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	20,375	40,378	56,040	50,852	-249	-6,652	27,664	120,798	-57,898	-36,494	12,941	17,371	22,099	784,803	-29,183	81,381	15,024	55,036	-37,435	-56,473	-3,650	-12,620	-16,792	-44,149	-51,392	-12,527	-36,833	-16,290	-90,720	-42,797	-423,560	-85,142	68,617	-90,926	-81,989	-67,501	-69,797	7,445	-33,502	-38,115	-61,990	-53,020	-21,533	-39,810	-53,012	-5,357	-32,006	-23,972	-26,735	-17,653	-5,077	-4,371	-12,189	217,334	-477	1,151	4,711	6,640	1,312	-13,152	24,506	829	3,810	1,686	2,570	-5,216	-3,864	-9,293	-10,391	-7,036	-1,325	-9,780	-14,996	-15,476	-21,340	-22,458	-82,422	-29,478	-55,598	-19,945	-25,727	-21,291	-9,097	-19,683	-19,330	-17,109	-14,411	-34,922	-34,922	-11,015	-11,969	-9,700	-10,394	-8,148	-7,086	-11,736	-9,072	-7,600	-6,800	-19,700
Net Income Applicable To Common Shares	0	40,378	56,040	50,852	-249	-6,652	27,664	120,798	-57,898	-36,494	12,941	17,371	22,099	784,803	-29,183	81,381	15,024	55,036	-37,435	-56,473	-3,650	-12,620	-16,792	-44,149	-51,392	-12,527	-36,833	-16,290	-78,711	-42,797	-423,560	-85,142	68,617	-90,926	-81,989	-67,501	-69,797	7,445	-33,502	-38,115	-61,990	-53,020	-21,533	-39,810	-53,012	-5,357	-32,006	-23,972	-26,735	-17,653	-5,077	-4,371	-11,515	217,334	-477	1,151	4,711	6,641	1,312	0	24,506	829	3,810	1,686	2,570	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	20,375	40,378	56,040	50,852	-249	-6,652	27,664	120,798	-57,898	-36,494	12,941	17,371	22,099	784,803	-29,183	81,381	15,024	55,036	-37,435	-56,473	-3,650	-12,620	-16,792	-44,149	-51,392	-12,527	-36,833	-16,290	-78,711	-42,797	-423,560	-85,142	68,617	-90,926	-81,989	-67,501	-69,797	7,445	-33,502	-38,115	-61,990	-53,020	-21,533	-39,810	-53,012	-5,357	-32,006	-23,972	-26,735	-17,653	-5,077	-4,371	0	217,334	-477	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	11,946	11,961	8,857	8,240	5,084	320	-1,354	-1,986	-2,101	-2,043	654	-1,365	-1,678	-5,593	-3,757	-1,671	-1,719	2,403	-1,001	-429	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	12,612	11,943	0	4,999	2,505	1,820	3,094	2,004	4,296	1,088	4,142	3,083	4,212	5,167	0	0	5,855	6,113	25,644	5,870	-14,538	5,302	4,527	3,723	2,763	2,549	2,762	1,529	1,222	1,436	1,174	1,158	819	370	1,869	1,210	522	785	-110	-1,305	487	-10,103	512	442	638	-229	23	-1,782	131	240	0	329	171	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,396,472	-2,396,472	599,118	0	198,700	0	0	0	198,700	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	14,219	22,830	56,771	60,466	-13,932	2,775	39,152	29,993	-65,880	-53,219	11,672	25,086	-44,840	-55,941	-40,945	104,961	-9,162	4,010	-41,354	-53,951	-38,148	-15,741	-25,263	-44,372	58,047	-13,727	-38,812	-20,208	-89,621	-60,085	-572,806	-80,917	101,319	-81,873	-64,240	-65,860	-58,756	11,203	-18,882	-26,456	-52,310	-50,724	-20,052	-32,921	-46,904	-10,491	-30,954	-21,866	-21,435	-15,517	768	2,294	-3,350	-1,939	3,043	2,790	6,382	10,133	4,313	-4,401	32,056	2,351	4,530	818	-9,370	-17,501	-13,601	-16,815	-11,563	-4,116	-1,337	-7,658	-12,826	-13,174	-18,774	-24,429	-79,565	-26,622	-53,843	-19,335	-25,113	-20,670	-9,477	-20,543	-26,251	-15,046	-12,975	-22,550	-10,903	-9,673	-10,668	-9,058	-10,024	-8,247	-7,188	-7,542	-9,099	-7,800	-6,100	-20,300
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	631,988	563,135	537,827	532,479	562,038	507,761	494,646	490,032	515,690	461,961	490,021	460,944	496,957	532,725	470,430	456,603	473,605	457,087	444,117	454,696	421,362	407,447	418,108	417,819	425,258	347,875	356,260	323,953	389,712	339,981	273,819	317,653	297,415	290,777	314,763	269,124	289,610	233,144	210,669	178,008	199,183	187,598	156,862	160,849	178,842	137,165	152,925	136,187	129,309	125,902	109,863	107,162	104,964	99,689	88,907	82,163	80,700	70,674	78,474	78,381	67,220	70,295	59,644	59,578	54,224	42,507	42,485	39,653	33,582	29,043	24,787	21,470	22,301	20,753	22,400	29,418	97,453	26,803	22,962	19,335	25,113	20,670	21,577	24,039	29,386	18,615	16,398	11,794	11,794	13,417	14,332	12,458	13,162	11,054	10,271	10,840	11,375	9,800	7,700	22,600
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	26,861	25,685	25,419	26,421	24,553	24,802	25,271	27,343	25,986	26,839	27,231	27,983	27,358	26,634	25,216	25,964	25,790	30,739	26,344	22,427	24,716	26,345	20,977	23,633	28,664	20,700	19,085	19,412	20,107	28,309	28,252	20,244	1,881	15,727	15,182	14,397	16,823	14,220	13,678	12,023	9,384	13,375	12,941	11,564	11,857	11,667	11,173	10,598	9,628	9,350	8,531	8,585	7,931	7,819	6,577	5,410	4,861	5,182	5,829	5,103	10,226	3,367	3,007	1,031	260	-149	136	843	2,561	3,086	3,776	2,535	2,775	2,429	2,405	2,466	599	6,208	4,221	2,251	2,385	2,932	2,040	2,085	1,884	2,381	2,178	839	839	2,203	2,062	1,900	1,995	1,907	1,697	1,734	2,358	2,000	1,200	1,000
Research Development	206,250	191,314	177,363	171,846	172,751	157,829	158,190	160,836	161,092	157,869	161,107	148,725	156,667	147,053	182,139	142,257	172,812	172,963	185,641	183,591	175,390	161,408	175,582	183,948	168,608	154,103	143,039	145,003	175,242	160,831	167,039	158,793	176,118	158,713	157,901	142,074	142,067	125,686	107,702	86,166	97,312	88,064	85,661	83,743	84,363	66,209	77,812	73,834	57,908	58,577	52,909	45,017	42,197	39,366	35,649	30,097	27,443	26,991	26,324	34,358	25,732	26,175	23,755	17,628	24,015	17,241	19,186	18,159	20,572	18,105	15,779	12,279	12,683	13,894	14,822	14,992	12,114	11,806	12,292	13,887	17,587	14,505	11,731	17,758	13,226	14,675	13,336	13,441	13,441	10,143	11,715	9,984	10,685	8,529	7,917	8,663	9,206	7,700	6,500	16,300
Selling And Marketing Expenses	133,200	121,900	115,600	117,700	124,600	111,300	109,400	104,900	113,100	97,000	100,900	94,200	97,000	0	97,000	0	0	0	0	0	0	0	0	0	67,000	67,000	0	0	0	0	0	0	0	0	0	0	137	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,192	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	141,800	102,100	99,736	105,303	121,109	105,500	87,400	89,700	104,500	86,300	83,300	80,100	195,543	179,450	78,400	187,295	187,900	170,112	160,754	162,158	164,171	148,566	153,280	138,336	160,280	63,532	143,505	120,019	142,958	118,758	109,577	105,300	113,907	94,044	101,514	92,806	99,632	74,604	68,089	60,069	71,809	61,841	50,656	51,050	55,049	46,337	51,539	45,248	48,454	44,880	41,015	41,037	42,098	38,348	37,277	34,000	36,528	28,667	30,527	28,568	28,730	28,964	25,203	23,669	23,892	19,713	17,649	16,284	13,971	12,292	11,871	10,896	11,076	9,797	10,117	10,567	13,302	12,761	7,539	3,689	5,475	1,662	4,460	3,024	4,421	3,940	3,062	3,926	0	2,993	2,309	2,203	0	2,331	2,190	1,996	0	2,000	1,100	6,100
Tax Provision	-1,048	1,291	14,770	5,905	-17,309	4,748	7,187	13,389	-8,676	-9,666	1,215	5,857	-62,284	-846,019	-13,090	19,971	-24,805	-45,214	-4,460	3,516	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	496,510	422,709	394,145	390,230	434,748	391,473	371,520	373,067	395,940	358,424	362,959	340,778	370,819	343,932	372,463	345,229	377,706	360,138	366,681	365,514	346,343	328,554	339,089	335,486	349,263	288,395	299,955	273,947	325,565	289,243	222,202	274,535	249,371	254,058	274,885	236,311	243,792	203,224	179,459	155,192	174,562	159,544	134,295	140,349	152,310	112,546	129,351	119,082	107,790	103,457	90,600	86,366	84,495	81,686	74,506	64,751	63,971	55,704	58,626	64,019	55,555	56,232	50,051	42,390	49,000	38,047	37,928	35,536	29,966	26,431	23,998	19,748	20,973	20,589	21,922	28,758	94,148	26,768	22,349	19,335	25,113	20,670	21,577	24,039	29,386	18,615	16,398	12,654	12,654	13,136	14,024	14,087	14,977	12,767	11,804	12,393	13,569	11,700	8,800	23,400
Total Other Income Expense Net	5,108	18,839	14,039	-3,709	-3,626	-4,679	-4,301	104,194	1,407	9,102	1,830	-493	6,333	318	2,429	57,557	11,100	3,409	15,426	1,423	26,893	2,121	22,742	-104	128,393	14	323	2,949	4,261	1,619	-600,670	63	170,326	-467	-9,325	99	572	67,201	-686	-185	200	92	-286	-173	-2,025	-1,654	-2,122	-3,026	-581	-5,544	-667	-542	-14,550	-639	-864	236	-821	-680	1,039	-6,400	-4,634	-572	-587	-533	9,366	8,446	6,550	6,163	8,985	1,744	4,745	3,800	3,072	3,388	3,303	2,076	-63,267	-507	-37,143	-1,759	-2,051	-4,503	-5,386	-3,257	-2,438	-2,350	-2,461	-14,272	-14,272	-1,864	-1,736	-1,108	-1,067	-590	-698	-4,980	-673	-500	-400	-200
Total Revenue	646,207	585,965	594,598	592,945	537,538	505,344	533,798	519,359	449,810	408,742	501,693	486,030	452,117	476,784	429,485	502,069	454,443	461,097	387,763	400,745	353,214	391,706	372,845	373,447	358,305	334,148	317,448	303,745	300,091	279,896	300,131	236,736	227,936	208,904	250,523	203,264	230,854	176,847	191,787	151,552	146,873	136,874	136,810	127,928	131,938	128,117	124,019	116,649	107,846	113,425	110,631	109,456	101,614	97,750	91,950	84,953	87,082	80,807	82,787	73,980	99,276	72,646	64,174	60,396	44,854	25,006	28,884	22,838	22,019	24,927	23,450	13,812	9,475	7,579	3,626	4,989	13,897	181	4,563	0	-15,596	12,100	12,100	3,496	3,135	3,569	3,423	891	891	3,744	3,664	3,400	3,138	2,807	3,083	3,298	2,276	2,000	1,600	2,300

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	2,419,226
Cost of Revenue	-577,065
Gross Profit	1,842,161	1,842,161

Operating Income (+$)
Gross Profit	1,842,161
Operating Expense	-1,684,564
Operating Income	157,597	157,597

Operating Expense (+$)
Research Development	746,773
Selling General Administrative	448,900
Selling And Marketing Expenses	488,400
Operating Expense	1,684,564	1,684,073

Net Interest Income (+$)
Interest Income	49,005
Interest Expense	-17,335
Other Finance Cost	-2,472
Net Interest Income	34,142

Pretax Income (+$)
Operating Income	157,597
Net Interest Income	34,142
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	188,563	126,631 EBIT - interestExpense = 140,262 188,563 184,980
Interest Expense	17,335
Earnings Before Interest and Taxes (EBIT)	157,597	205,898
Earnings Before Interest and Taxes (EBITDA)	261,983

After tax Income (+$)
Income Before Tax	188,563
Tax Provision	-4,657
Net Income From Continuing Ops	147,021	183,906
Net Income	167,645
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	2,261,629
Total Other Income/Expenses Net	30,966	-34,142

Technical Analysis of Biomarin
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biomarin. The general trend of Biomarin is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biomarin's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (28.6%)		Bearish trend (-28.6%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Biomarin Pharmaceutical Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 94.15 < 94.51 < 99.25.

The bearish price targets are: 88.74 > 83.44 > 78.87.

Tweet this

Biomarin Pharmaceutical Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biomarin Pharmaceutical Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

MA 20 trending up: The MA 20 is trending up. +1
Close > MA 20: The price is above the MA 20. +1
MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
MA 50 trending up: The MA 50 is trending up. +1
Close > MA 50: The price is above the MA 50. +1
MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Biomarin Pharmaceutical Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biomarin Pharmaceutical Inc. The current macd is 1.06460381.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biomarin price going up in the near term. +2
MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Biomarin. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Biomarin price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1

Biomarin Pharmaceutical Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Biomarin Pharmaceutical Inc. The current adx is 21.99.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biomarin shares, leading to potential upward momentum in its price. +1
PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1

Biomarin Pharmaceutical Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biomarin Pharmaceutical Inc. The current sar is 93.36.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Biomarin Pharmaceutical Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biomarin Pharmaceutical Inc. The current rsi is 57.87. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Biomarin Pharmaceutical Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biomarin Pharmaceutical Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biomarin price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

Biomarin Pharmaceutical Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biomarin Pharmaceutical Inc. The current cci is 73.60.

Biomarin Pharmaceutical Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biomarin Pharmaceutical Inc. The current cmo is 16.60.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1

Biomarin Pharmaceutical Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Biomarin Pharmaceutical Inc. The current willr is -42.50645995.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biomarin is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Biomarin Pharmaceutical Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biomarin Pharmaceutical Inc. The current atr is 1.73998131.

Biomarin Pharmaceutical Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biomarin Pharmaceutical Inc. The current obv is 32,124,012.

Biomarin Pharmaceutical Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biomarin Pharmaceutical Inc. The current mfi is 58.44.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

MFI > 50: +1

Biomarin Pharmaceutical Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Biomarin Pharmaceutical Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-11-30	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-01	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-05	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2023-12-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-08	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-13	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-14	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-20	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2023-12-21	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-03	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-12	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-17	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-23	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-25	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-01-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-30	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-31	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-06	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-13	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-16	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-21	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-22	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-23	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-29	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-21	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-22	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-25	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-26	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-03-27	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-03-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-02	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-03	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-09	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-10	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-04-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-15	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-04-18	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside

6.3. Candlestick Patterns

Biomarin Pharmaceutical Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Biomarin Pharmaceutical Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	57.872
Ma 20	Greater than	Ma 50	88.352
Ma 50	Greater than	Ma 100	87.642
Ma 100	Greater than	Ma 200	90.637
Open	Greater than	Close	90.250
Total			4/5 (80.0%)

Create your own Symbol Scanner

Get notifications about Biomarin Pharmaceutical Inc

I send you an email if I find something interesting about Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc Buy, Hold or Sell?

Let's analyse Biomarin together

Get notifications about Biomarin Pharmaceutical Inc

Quick analysis of Biomarin (30 sec.)

What can you expect buying and holding a share of Biomarin? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Biomarin (5 min.)

$90.07

$25.81

$-2.57 - $17.47

$23.24 - $43.28

2. Growth of Biomarin (5 min.)

Is Biomarin growing?

How much money is Biomarin making?

How much money comes from the company's main activities?

3. Financial Health of Biomarin (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Biomarin? (5 min.)

What can you expect buying and holding a share of Biomarin?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Biomarin

About Biomarin Pharmaceutical Inc

Financial Health

Valuation

1.1. Profitability of Biomarin Pharmaceutical Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Biomarin Pharmaceutical Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Biomarin Pharmaceutical Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Biomarin Pharmaceutical Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Biomarin Pharmaceutical Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Biomarin Pharmaceutical Inc
Buy, Hold or Sell?